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SteroidogenesisEndocrine-related endpoints in animals have been reported to respond to high doses of methyl tertiary-
butyl ether (MTBE), however, a systematic and transparent evaluation of endocrine potential has not
been published. Resolving whether MTBE exhibits endocrine activity is important given regulatory and
public interest in endocrine disrupting substances and their potential for causing adverse effects in
humans or wildlife. A weight-of-evidence (WoE) analysis was conducted, focusing on hypotheses related
to the potential for MTBE to interact with estrogen, androgen, and thyroid pathways, and steroidogenesis.
To reach scientiﬁcally justiﬁed conclusions based on the totality of evidence, this WoE procedure
involved a semi-quantitative relevance weighting of each endpoint for each hypothesis and systematic
consideration of each endpoint in various study designs. This procedure maximized use of an extensive
body of relevant and reliable literature on MTBE with evidence supporting or opposing a given mode of
action hypothesis. Evaluating the strength and consistency of observations from many MTBE studies also
provided a way to assess whether high doses used in experiments with MTBE confound identiﬁcation of
direct endocrine system responses. Based on results of studies using mammalian and ﬁsh models and
in vitro screening assays, this WoE assessment reveals that MTBE lacks direct endocrine activity.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction and background
Methyl tertiary-butyl ether (MTBE, CAS RN 1634-04-4) is an
additive in gasoline used to increase the efﬁciency of combustion
and bring associated environmental beneﬁts. MTBE also has minor
uses as a solvent in closed systems. Endocrine-related responses in
rodents have been observed at high doses of MTBE, and endocrine
activity has been theorized as a mode of action (MoA) responsible
for some of these effects (Bird et al., 1997; McGregor, 2006; Cruzan
et al., 2007). However, to date, there has been no comprehensive,
detailed, and systematic review of the database on MTBE that
weighs the evidence with attention focused on speciﬁc endocrine
pathways. Given regulatory and public interest in endocrine active
substances and their potential for causing adverse effects in
humans or wildlife, resolving whether MTBE exhibits endocrine
activity is important. The goal of this paper is to determine if MTBE
acts through an endocrine MoA. To achieve this we used a robustand transparent WoE process. The WoE analyses performed were
focused on speciﬁc hypotheses addressing the estrogen, androgen,
and thyroid hormonal pathways and steroidogenesis, including an
analysis of studies related to aromatase, the steroidogenic P450
enzyme that converts androgens to estrogens. Studies pertaining
to both mammalian and non-mammalian organisms were
considered and used in the WoE assessment if relevant to any of
the hypotheses.
A WoE approach has been in the health risk assessment lexicon
for many years but may have different meanings to different peo-
ple (Weed, 2005). The US Environmental Protection Agency Endo-
crine Disruptor Screening Program (US EPA EDSP) has developed
guidance for using a WoE approach to evaluate and integrate all
relevant scientiﬁc and technical information from Tier 1 screening
tests to draw conclusions about the need for further testing (US
EPA, 2011). Others further recommend objective, systematic and
structured hypothesis-driven approaches for WoE evaluations
(Rhomberg et al., 2010; Bars et al., 2011, 2012; Borgert et al.,
2011a,b, 2014). The WoE approach chosen for this analysis is
semi-quantitative, based on ranking of the relevance of responses
following a pre-deﬁned framework that should be blind to the
study outcomes, with an assessment of the reliability of data
applied to each endpoint and study (Borgert et al., 2011a,b, 2014).
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observed in one or more study designs, and a semi-quantitative
weighting of the relevance of each type of response to a given
hypothesis, to reach scientiﬁcally justiﬁed conclusions based on
the totality of the evidence. It is important to emphasize that, unlike
some approaches that weigh relevance of an effect observed strictly
on the basis of type of study design (e.g., in vivo vs. in vitro), this
analysis is aimed at discerningwhich endpoints are the best predic-
tors of mode of action. Study purpose, study design and the ability
of the design to meet that intended purpose are also carefully con-
sidered in terms of reliability. In the end, conclusionswere based on
a simple classiﬁcation system of pro- or anti-hormone effects, and
then evidence for (or against) direct interaction with the endocrine
system versus secondary effects of toxicity is discussed in more
detail. Indirect effects of systemic toxicity, unrelated to a primary
endocrine mode of action, are an important consideration for regu-
latory classiﬁcation of any chemical, including MTBE.
This evaluation is timely since the US EPA has includedMTBE on
a list of chemicals to be screened under the EDSP. Listing is based
on potential exposure and other statutory considerations, but does
not imply that the US EPA suspects those chemicals of interacting
with endocrine systems of humans or other species. Tier 1 of the
EDSP uses a battery of assays to determine if a chemical has the
potential to interact with the endocrine system. Identifying
adverse effects is not the focus of the Tier 1 battery, and no single
assay alone is sufﬁcient to determine if there is the potential for
the chemical to interact with the endocrine system. Further testing
of those chemicals that show potential to interact would be needed
to identify adverse effects and, with an understanding of relevant
environmental exposure, quantify the risk.
The main focus on endocrine activity is not intended to imply
that this should be viewed as the most important toxicological
concern for MTBE. Acknowledging that many study endpoints can
be affected by multiple modes of action is key to conducting an
objective and scientiﬁcally sound WoE analysis (Rhomberg et al.,
2010). The appearance of increased (or decreased) hormone-depen-
dent cell growth, changes in hormone-dependent organ weights
and histology, in vitro hormone receptor-ligand changes, altered
hormone concentrations, include some of the observations that
may collectively imply the potential for endocrine activity when
there is sufﬁcient strength and consistency of the responses.
However, none alone is sufﬁcient evidence of an endocrine mode
of action, and these may also be affected by non-endocrine mecha-
nisms, for example induced or diminished catalytic activity of liver
enzymes that metabolize steroid hormones.
An objective evaluation of potential endocrine activity must
also consider the fact that many toxicology studies administer
doses of chemicals that far exceed possible occupational, con-
sumer, or environmental exposures. This conservative approach
to testing chemicals has some justiﬁcation, but one must also
always keep in mind that excessive doses of any chemical increase
the probability of systemic toxicity and effects on endocrine end-
points mediated indirectly by other effects. Typical concentrations
of MTBE in air and water are many orders of magnitude below the
exposures tested in MTBE toxicology studies using experimental
animals. Likewise, tissue concentrations of MTBE measured in
human populations when MTBE was in widespread use are also
many orders of magnitude below the concentrations tested in
in vitro toxicology studies.
2. Methods
2.1. Literature search
National Library of Medicine search engines, PubMed and
Toxnet, were used with the following keywords: methylt(ertiary)-butyl ether, MTBE, tert-butyl methyl ether, 2-methoxy-
2-methyl-propane and toxicity. Open peer-reviewed literature
was supplemented with additional unpublished and other ‘grey’
literature resources in comprehensive MTBE reviews (ATSDR,
1996; McGregor, 2006), as well as studies listed in the European
Union risk assessment report (EU, 2002) and updated in the REACH
submission (ECHA, 2012).
Maximal use of all existing relevant and sufﬁciently reliable
information was a goal. Consistent observations in multiple studies
and multiple species with different experimental designs can
reduce unknown bias or confounding and increase support for or
against a given mode of action hypothesis (Boobis et al., 2008). Risk
assessors and others increasingly acknowledge that all of these
types of studies can have merits, whether or not they were con-
ducted with strict adherence to standard guidelines and good lab-
oratory practices (GLP) (McCarty et al., 2012; Batke et al., 2013). All
studies were ﬁrst considered for relevance and then for reliability,
if endpoints measured were deemed sufﬁciently relevant.
An MTBE study did not have to have an endocrine focus in order
to be considered relevant. Results of reproduction/fertility and pre-
natal developmental toxicity studies that encompass different life
stages, and also studies that provide carcinogenicity information
on endocrine organs were all considered relevant to a consider-
ation of endocrine activity (OECD, 2012). All endpoints associated
with the endocrine pathways addressed by the hypotheses were
considered relevant, including, for example, subchronic, or chronic
general toxicology studies reporting gonadal, thyroid or hormone-
dependent weights of organs or histopathology. If an MTBE study
had an endocrine organ endpoint related to any of the hypotheses
then it was included in the initial literature review.
A few studies were eliminated from consideration after the
initial review of literature. For example, a study with exposure to
gasoline vapor condensate with and without MTBE (Benson et al.,
2011) was not included due to the confounding effects of exposure
to various gasoline components. Three in vitro studies (Li and Han,
2006; Li et al., 2007, 2009) using cells from a rodent endocrine
organ, speciﬁcally mouse or rat testis, had no measured endpoints
that could be related to the hypotheses so were also excluded
before reliability scoring.
2.2. Data quality assessment
Considerable toxicity testing of MTBE was conducted during the
1980s (Duffy et al., 1992) before adoption of study protocols and
guidance for evaluating the potential for endocrine activity. Some
study designs were generally similar to a standard test protocol,
but relatively few were similar enough to qualify as guideline stud-
ies in the context of current methods for evaluating endocrine
activity. While it is appropriate to have greater conﬁdence in stud-
ies that have employed standardized and validated test methods
and were conducted according to GLPs (Becker et al., 2009;
Borgert et al., 2011b; McCarty et al., 2012), a non-guideline study
could still be considered reliable if the methods were sufﬁciently
well-documented and the results transparently and thoroughly
reported. A prevailing objective was to retain as many sufﬁciently
reliable studies as possible for the WoE analysis.
The data quality discussion about primary, secondary and ter-
tiary validity in Borgert et al. (2011a and supplement) was con-
sulted, as were other consensus opinions on principles and
processes for judging reliability and quality of study designs and
data (Klimisch et al., 1997; Schneider et al., 2009; Tluczkiewicz
et al., 2013). Sufﬁcient transparency in the documentation
(secondary validity) and classiﬁcation by Klimisch score became
one of the most important criteria, insofar as adequate documenta-
tion of study details is necessary for making further judgments
about study and speciﬁc endpoint reliability for the WoE analysis.
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data quality assessment; for example, if results were likely to have
been confounded by other factors or the result was not repeated
either within the study or between studies then that was noted
during the literature review. Whether or not the study design
was capable of addressing the hypothesis in question and estab-
lishing causality (tertiary validity) was considered, although the
lack of speciﬁc and probative positive controls in most studies
reduced the ability to conﬁrm biological plausibility. Evaluating
validity of speciﬁc studies took place ﬁrst during the detailed
review of each study to extract potentially relevant endpoints,
and continued throughout the analysis of the WoE information
included in the tables.
In the current assessment, a Klimisch reliability score of 1 was
possible only for studies performed according to a regulatory or
near-regulatory guideline following GLP, so those that were not
so identiﬁed initially ranked no higher than a 2. Recommendations
from the ‘‘ToxRTool’’ (Schneider et al., 2009) were taken into con-
sideration when evaluating the level of detail in study reports.
Some publications describing non-guideline studies contained
multiple experiments. A few included both in vitro and in vivo
experiments that were evaluated independently, so it was possible
for data from different experiments in a series described in a single
publication to receive different scores. Scoring and interpretation
of scores in the ﬁnal WoE evaluation was as follows: 1 – Reliable
without restriction (useful, check relevance for intended purpose);
2 – Reliable with restrictions (potentially useful, check relevance
for intended purpose); 3 – Not reliable (signiﬁcant methodological
or documentation deﬁciencies, might be useful as supportive infor-
mation); and 4 – Not assignable (documentation insufﬁcient, but
may still be useful as supportive information).
One abstract was never published as a full peer-reviewed paper
and was eliminated at this stage with a Klimisch score of 4 for lack
of detail (Almeida et al., 2004). Reliability of a published male rat
study (Zavgorodnij et al., 2013) became questionable and was
given a score of 3 after a close review of content revealed that
method descriptions lacked sufﬁcient detail for assessing reliabil-
ity of the results. A published paper could be relevant and even suf-
ﬁciently well documented, but one or more endpoints considered
unreliable because of some shortcoming in methods or details
missing from the description of that method that caused concern
about reliability. For example, an in vitro experiment involving
MTBE exposure of testosterone-producing isolated rat Leydig cells
(de Peyster et al., 2003) lacked a nonspeciﬁc cytotoxicity measure-
ment for comparison. That experiment was ultimately assigned a
score of 3, whereas the in vivo companion studies in that report
were considered sufﬁciently reliable to be scored as 2. Study infor-
mation with reliability scores of 1 or 2 qualiﬁed for use in the ﬁnal
WoE analysis.
2.3. Weight of evidence analysis methods
The WoE approach used to evaluate the MTBE data was based
on a relatively new method (Borgert et al., 2011a, 2014). This
approach is transparent and systematic, and is also referenced in
OECD and US EPA guidance for evaluating chemicals for endocrine
disruption (OECD, 2012; US EPA, 2011). The method is a
semi-quantitative hypothesis-testing approach for ranking or
weighting study endpoints based on their relevance for a particular
hypothesis. The hypotheses considered were whether or not MTBE
exhibits the potential to interact with components of the estrogen,
androgen, or thyroid pathways as an agonist or antagonist, or if
MTBE induces or inhibits the steroidogenic pathway. While the
Borgert et al. (2011a, 2014) procedure for WoE was primarily
developed to evaluate the data coming from the US EPA EDSP,
the framework and methodological approach is broadly applicable.Endocrine relevant endpoints were identiﬁed from the large
MTBE database. Study endpoints were assigned one of three ranks
using the criteria designated in Borgert et al. (2014). Ranking the
endpoints a priori allows for a transparent and objective
assessment of the data and their importance in informing each
hypothesis.
Rank 1 endpoints are speciﬁc and sensitive for the hypothesis
being evaluated. These can be interpreted without clariﬁcation
from other endpoints and are rarely confounded by non-speciﬁc
activity. Rank 1 endpoints are in vivo measurements only as
in vitro responses are typically not able to identify a relevant
biological effect.
Rank 2 endpoints are also speciﬁc and sensitive for the hypoth-
esis being evaluated but are less informative than Rank 1 as
these are often subject to confounding inﬂuences or other
modes of action. Rank 2 endpoints include both in vitro and
in vivo data.
Rank 3 endpoints are relevant for the hypothesis being evalu-
ated but only when corroborative of Rank 1 and 2 endpoints.
Rank 3 endpoints are not speciﬁc for a particular hypothesis
and include some in vitro and many apical in vivo endpoints.
Not all study endpoints are equally meaningful for each hypoth-
esis. In assigning ranks or ‘‘weighting’’ the endpoints, consideration
was given to how well the data informed the speciﬁc hypothesis
being tested. Thus, study endpoints do not always fall into the
same rank for each of the hypotheses. For example, vitellogenin
(VTG), the egg yolk protein in ﬁsh, is sensitive and speciﬁc for
the estrogen agonist hypothesis. However, it is not relevant for
the thyroid agonist or antagonist hypotheses. In addition, non-spe-
ciﬁc endpoints such as decreases in concentrations of hormone or
VTG or altered gonado-somatic index (GSI) may be related to
effects on the liver and are not necessarily a primary endocrine-
related response. The endpoints identiﬁed from the review of the
MTBE literature database relevant for each of the eight hypotheses
were ranked and listed in tables. There are a number of endpoints
in the MTBE literature that appear relevant for inclusion in an
assessment of endocrine activity but are not in the US EDSP
screens, and thus assignment of relevance ranks has not previously
been proposed. Endpoints not evaluated by Borgert et al. (2014),
including endpoint responses in adult animals versus pubertal ani-
mals, were included in the MTBE ranking tables only if literature
was found that established the ability of that endpoint to address
one of the hypotheses. The authors acknowledge that these
proposed rankings could change as better understanding is
achieved in evaluating and interpreting potential endocrine
activity. However, ranking the endpoints a priori allows for a
transparent and objective assessment of the data and their
importance in informing each hypothesis.
After the endpoints were ranked in tables the applicable studies
and responses were entered. Each hypothesis was evaluated inde-
pendently. According to Borgert et al. (2011a, 2014), positive
responses in rank 1 endpoints are a preliminary indication that
the hypothesis is supported. Positive responses in both ranks 1
and 2 endpoints provide additional evidence that the hypothesis
is supported. Rank 3 endpoints were then reviewed to determine
consistency in response across the tested hypothesis. Conversely,
negative responses in rank 1 endpoints are a preliminary indica-
tion that the hypothesis is not supported. Consistent negative
responses in ranks 1 and 2 provide sufﬁcient evidence that the
hypothesis is not supported. In those cases, rank 3 endpoints are
not meaningful since these are not as sensitive and speciﬁc for
the hypothesis, being easily impacted by other mechanisms or
modes of action. In situations where rank 1 endpoints are negative
or there are none for that hypothesis, but there are positive rank 2
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relevance and the strength of the response was considered.
It is important to consider consistency of response in evaluating
the data. Not unexpected for substances with a large database of
studies conducted by a variety of methodologies and researchers,
there are a number of examples in the MTBE database of conﬂict-
ing responses (i.e., positive and negative for the same endpoint), as
well as patterns of responses across endpoints that are not what
would be expected by a particular mode or mechanism of action.
It is likely that the extremely high doses used in many studies
result in toxicity or physiological changes that do not have a pri-
mary basis in an endocrine pathway interaction. For example,
Marty et al. (2011) has noted that systemic toxicity can impact
many of the endocrine endpoints in the pubertal rat studies. Others
have alerted investigators to the confounding effects of stress and
systemic toxicity on measures of endocrine and other effects
(Everds et al., 2013; Brown et al., 2000; Pellegrini et al., 1998).
Reduced body weight gain, as well as ataxia and lethargy after dos-
ing, have been noted in a number of MTBE studies (see Discussion
Section 5). US EPA and OECD test guidelines specify that the high-
est dose should be at or just below the maximum tolerated dose
(MTD), up to a limit of 1000 mg/kg/day in the mammalian studies
(US EPA, 2009a,b,c,d; OECD, 2007a, 2009). This is also the case with
many of the guideline chronic studies evaluating reproductive and
developmental endpoints (e.g., OECD, 2007b). Most of the studies
performed with MTBE, however, used top doses well above this
limit dose guidance, making it difﬁcult to differentiate between
primary endocrine activity and responses that are secondary to
overt toxicity or signiﬁcantly altered toxicokinetics.
2.4. Examples of ranking the relevance of responses related to the
different hypotheses
Scientiﬁc justiﬁcations for most of the endpoint ranking under-
taken in this analysis are explained in Borgert et al. (2014) so will
not be reiterated in detail. Some examples are discussed here for
readers unfamiliar with the approach.
When considering estrogen or androgen pathway-related
hypotheses, few in vivo assays are recognized as being speciﬁc
and sensitive enough to be rank 1 for detecting ‘‘estrogen-like’’
and ‘‘androgen-like’’ compounds. A study based on a rodent utero-
trophic assay design can detect estrogen agonists and antagonists
using uterine weight as an endpoint, but only the estrogen agonist
response of an increase in uterine weight has been formally vali-
dated for the uterotrophic assay.
The guideline Hershberger assay requires the measurement of
ﬁve androgen-dependent tissues (US EPA, 2009a). A Hershberger-
like assay (de Peyster et al., 2003) measured weights of prostates
and seminal vesicles in castrated near-peripubertal rats. Although
it differed in several respects from a guideline study (see Supple-
mental material), weights of prostates and seminal vesicles from
this study were still considered rank 1 endpoints.
The ﬁsh short-term reproduction test (FSTRA) (US EPA, 2009e)
is a multi-modal assay with endpoints that address estrogen,
androgen, and steroidogenic pathways. VTG, in particular, is a sen-
sitive and speciﬁc indicator of estrogen agonist potential when
increased in male ﬁsh. Most of the other endpoints measured in
this study, however, are ranks 2 or 3 as these are predominately
apical in response. Higher level endpoints that reﬂect an integra-
tion of all underlying biological processes contribute to an assess-
ment of a chemical’s overall effect, but are not typically helpful for
elucidating a mode of action.
Several in vitro assays have been sufﬁciently studied and vali-
dated for use in endocrine activity screening programs. As the
in vitro screens lack metabolic capability and can be confounded
by cytotoxicity, these are considered ranks 2 or 3 in the WoEranking framework. Estrogen (ERB) and androgen receptor binding
(ARB) assays were not designed to distinguish agonistic from
antagonistic effects. This limitation of dependence on responses
in other endpoints to further distinguish agonism from antagonism
resulted in receptor binding responses in no higher than rank 2.
The estrogen receptor transcriptional activation (ERTA) assay can
distinguish estrogen agonists from antagonists so was assigned a
rank of 2 for both estrogen hypotheses. The two hormone
endpoints (testosterone and estradiol) measured in the in vitro ste-
roidogenesis H295R cell screening assay, which was developed
speciﬁcally to determine if a chemical alters the steroidogenic
pathway by induction or inhibition, were both ranked 2 in the ste-
roidogenesis hypotheses. The in vitro aromatase activity assay
using recombinant human microsomes ranked 3 when assessing
steroidogenesis inhibition. Although speciﬁc to measuring the aro-
matase effect of interest, the assay can detect an inhibitory effect
on only one steroidogenic enzyme and generalized cytotoxicity, if
not controlled for, could produce an apparent decrease in aroma-
tase activity.
Reproductive, pre-/post-natal developmental effects studies,
and also carcinogenicity bioassays of MTBE that characterize histo-
pathology or weight of some hormone-producing or hormone-
dependent organs, provided additional information for a few
ranked endpoints. Other types of apical endpoints (e.g., pregnancy
and fertility indices, embryofetal mortality, skeletal and soft tissue
malformations and variations) are accepted as contributing to an
overall assessment of a chemical’s ability to cause some endocrine
system perturbation; however, these are not usually helpful for
elucidating a mode of action. Positive ﬁndings in these types of
reproductive or developmental endpoints do not usually help to
distinguish whether the effect observed is a result of direct or indi-
rect involvement of the endocrine system or whether it should be
classiﬁed as pro-hormonal or anti-hormonal.
Numerous factors must be considered when interpreting con-
centrations of serum hormones, organ weights, and histopathol-
ogy. Altered circulating hormone concentrations could be
secondary to many other primary changes involving non-endo-
crine mechanisms (e.g., increased metabolism of steroids by the
liver, excessive weight loss, ﬂuid retention in the body causing
dilution of blood components, to name but a few). Homeostatic
feedback control of hormone concentrations also means that single
time-point measurements in blood can sometimes miss an effect
or otherwise be unrepresentative of the trend and/or typical status
of hormone concentrations the animal experienced throughout the
study. Unless the response is well understood to be pro- or anti-
hormonal, the change is hard to interpret and apply the result to
an analysis of a speciﬁc hypothesis without additional information
from more direct measures of endocrine function. For these rea-
sons, hormone endpoints from these studies were not ranked 1
in this WoE analysis. That said, however, absence of any signiﬁcant
adverse ﬁndings in these types of studies, especially if consistent
across studies, would be considered useful information that lends
support for the position that the chemical has neither agonist nor
antagonistic interactions with a given hormonal pathway.3. Literature summary
3.1. Health effects studies of MTBE with endpoints relevant to
endocrine activity
A brief overview of the types of studies relevant for this WoE
evaluation is included here specifying route of exposure and range
of doses used for each study. These basic elements of study designs
complement other information about species and key endpoints
examined shown in the WoE tables discussed in Section 4. Readers
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the online Supplemental material containing much more about
experimental designs, strains of the species tested, other treatment
information (e.g., detailing timing and frequency if not daily, full
range of MTBE doses/concentrations tested, vehicles or other sub-
stances co-administered for comparison), and other ﬁndings in
these studies that helped to provide context for effects observed
(or not observed), but ultimately were not considered speciﬁc or
predictive enough to be included in the WoE tables. The Supple-
mental material also contains additional discussion of the reliabil-
ity of some studies and offers speciﬁc concerns about methods and
results that call into question the validity of their ﬁndings or con-
clusions. Other results, such as reduced amount of body-weight
gain or other signiﬁcant changes in non-endocrine organs, were
noted in the Supplemental material to help place any endocrine
ﬁndings into perspective.
Relevant positive (statistically signiﬁcant) and negative data
speciﬁcally related to ranked endocrine hypothesis endpoints were
extracted from the studies for theWoE tables. Additional key infor-
mation was also added to the tables to further facilitate analysis.
For example, the test species was noted with the study reference
in the tables in order to understand any species-speciﬁc response.
In addition, differences in endpoints evaluated and experiment
timing were noted in the Tables if results differed across multiple
experiments described in a report.
3.1.1. In vitro studies
In vitro studies of estrogen receptor binding (ERB) and estrogen
receptor transcriptional activation (ERTA) (Moser et al., 1998) were
part of a series of experiments investigating the suggestion that
MTBE had increased the frequency of liver tumors in female mice
in a cancer bioassay (Bird et al., 1997) by a MoA involving estrogen
insufﬁciency. These would not be considered as US EDSP screening
guideline studies but the test methods employed were similar. No
effect was observed when concentrations of MTBE were tested in
the ERB assay ranging from 1011 M to 104 M. Concentrations of
MTBE tested in the ERTA assay, also revealing no activity, ranged
from 108 M to 104 M. Formaldehyde and tert-butanol (TBA) were
also tested in the ERB assay and found to be without effect.
In addition, three GLP-compliant endocrine screening assays
following accepted guidelines were conducted using MTBE and
TBA, the predominant metabolite of MTBE (de Peyster et al.,
2014): (1) androgen receptor (AR) competitive binding in rat pros-
tate cytosol following the US EPA OPPTS 890.1150 guideline; (2)
aromatase inhibition activity in human recombinant microsomes
following the US EPA guideline OPPTS 890.1200; and (3) steroido-
genesis using the adrenal corticocarcinoma cell line H295R that
expresses all enzymes needed to synthesize testosterone and
estradiol, following the US EPA guideline OPPTS 890.1550 which
is equivalent to the OECD test guideline 456. Concentrations of
MTBE and TBA evaluated were 1010 M–103 M in the AR binding
and steroidogenesis assays, and 1010 M–104 M in the aromatase
inhibition assay. All of these in vitro endocrine assays showed
absence of an effect.
3.1.2. Endocrine-focused studies in female and male rodent models
Studies included in this section were focused on determining
whether MTBE altered one or more endocrine parameters in male
or female rodents. In general, these studies were designed to
address speciﬁc questions about effects of MTBE observed at high
doses in previous studies. In most instances, these studies were tar-
geted at answering speciﬁc questions, and included similarly high
doses to try to replicate conditions in the previous MTBE studies.
Female mice were used in several MTBE gavage and inhalation
studies designed to investigate MTBE mode of action using expo-
sures of 3 days to 8 months duration (Moser et al., 1996, 1998). Acentral question investigated in these studies was whether the
increased hepatic adenomas and decreased uterine cystic hyper-
plasias observed in female mice in an earlier cancer bioassay
(Bird et al., 1997) could be linked to hormonal modulation, and,
if so, whether the underlying cause could be increased hepatic
metabolism of estrogen. To be consistent with the highest MTBE
concentration used in that earlier cancer bioassay, 8000 ppm was
chosen for the inhalation concentration in these follow up experi-
ments examining mode of action. One of these studies (Moser
et al., 1996) focused on the involvement of the liver in effects seen
with MTBE, also comparing rates of metabolism of estradiol by
hepatocytes from female mice in treated and vehicle-control
groups. In that study, mice were gavaged with an 1800 mg/kg dose
of MTBE for 3 days. Speciﬁc P450 enzymes involved in steroid
metabolism were also examined in that study. In Moser et al.
(1998), the focus was more on effects on female mouse endocrine
organ weights, histopathology and tissue proliferation, estrous
cycle length, and evidence of involvement of estrogen receptors.
These female mice were exposed for 3 or 21 days or 4 or 8 months
to the MTBE vapor dose observed to be hepatocarcinogenic
(8000 ppm). This report also included the companion in vitro ERB
and ER transcriptional activation studies mentioned in the previ-
ous section. Main conclusions drawn from these studies were that
although effects observed in female mice administered MTBE
involve estrogen-dependent organs, these effects do not appear
to be mediated through estrogen receptors.
Another MTBE study in immature female mice with the same
general objective included an uterotrophic assay-type design aug-
mented by other measurements not required by the standard test
guideline (Okahara, 1999). In this study, 1500 mg/kg doses of
MTBE administered by gavage according to the standard test pro-
tocol caused no effect on uterine weight whether or not animals
were also dosed with estradiol, further supporting the notion that
MTBE does not directly act upon estrogen receptors. Collectively,
this experiment and the studies by Moser et al. provided informa-
tion about effects of MTBE on the female reproductive organs and
endocrine axis (uterine, ovarian, vaginal/cervical, pituitary), histo-
pathology and weight changes, estrous cycle length, circulating
estrogen concentrations, and in some cases other endpoints giving
insights at a more molecular level, speciﬁcally changes in ER
immunoreactivity, cell proliferation, and uterine peroxidase in
estrogen-sensitive tissues.
Male rodent models were used in other peer-reviewed experi-
mental studies, most consisting of multiple 14- or 28-day experi-
ments examining potential endocrine effects of high gavage
doses of MTBE in male rats (Williams et al., 2000; Williams and
Borghoff, 2000; de Peyster et al., 2003; Li et al., 2008). Responses
of male mice have been examined in a few additional experiments
discussed later (Billitti et al., 2005; de Peyster et al., 2008). The
highest doses used in the studies with rats ranged from 800 to
1600 mg/kg BW/day. The majority of these studies administered
MTBE by gavage to intact adult animals, although one experiment
used castrated rats gavaged with 800 mg/kg daily for 5 days in a
Hershberger-like study design (de Peyster et al., 2003, experiment
3). Because the main research question of that study was slightly
different from that of a routine endocrine screening study, the cas-
trated rats were slightly older than pubertal, and weights of only
two of the ﬁve androgen-dependent tissues recommended in stan-
dard guidelines were measured in animals with/without testoster-
one propionate supplementation. Li et al. (2008) reported having
purchased rats 28–30 days of age followed by a 10-day acclima-
tion, which would have made these animals only 38–40 days old
at study start and suggested that they might not have reached full
sexual maturity. If this is indeed the case, then results of those 2-
week and 4-week experiments may not be entirely consistent with
results seen in otherwise comparable studies involving older rats.
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drinking water at concentrations ranging from 80 to 8000 ppm
from 25 to 26 days of age through post-natal day (PND) 77 (de
Peyster et al., 2008). Adult male mice were exposed to MTBE daily
by gavage for 1 week to as much as 2000 mg/kg BW/day (Billitti
et al., 2005). Neither of these studies in mice observed any effect
on the endocrine-related endpoints evaluated.
High gavage doses (1000–1600 mg/kg) were included in the
majority of these male rodent studies. It was explicitly noted in
several of the studies that an objective was to understand the basis
of a reported increase in Leydig cell tumors seen in rats exposed to
high doses of MTBE (Belpoggi et al., 1995; Bird et al., 1997). Those
results are now considered highly suspect, but the ﬁndings were
taken seriously at that time and warranted follow up. Concerns
raised about the reliability of these Leydig cell carcinogenicity
study results included use of a non-standard cancer bioassay pro-
tocol in one of the studies (Belpoggi et al., 1995), and an unusually
low tumor incidence observed in a control group used for compar-
ison with MTBE-treated groups in the other study (Bird et al.,
1997).
Collectively, those types of studies provided information on
many different endocrine-related endpoints. Weights of testis
and male accessory sex organs were most often reported. Histopa-
thology of testis was also evaluated in a few of these studies. When
hormone concentrations were measured, they often included tes-
tosterone in blood and sometimes also in testicular interstitial ﬂuid
(TIF). Some experiments also measured one or more other hor-
mone concentrations in blood; for example, dihydrotestosterone
(DHT), estradiol, follicle stimulating hormone (FSH), luteinizing
hormone (LH), and prolactin. Information on effects of MTBE on
sperm quality parameters (count, motility, morphology) was found
in a few studies. Additional studies furnished information on
effects of MTBE on biochemical and molecular endpoints like aro-
matase and other P450 activities, and androgen binding protein
mRNA in male rat tissues. One of these studies found increased
activity of liver P450 isozymes playing a major role in testosterone
metabolism (Williams and Borghoff, 2000). One of the male rat
studies mentioned above (Williams et al., 2000, experiments desig-
nated A and B) provides some additional information about thy-
roid-stimulating hormone (TSH), triiodothyronine (T3), and
thyroxine (T4), while another measured thyroid weights in one
of several experiments (de Peyster et al., 2003, experiment 2). Lit-
erature discussing the effect of MTBE on the thyroid hormone
pathways is not as extensive as it is for estrogens and androgens,
although some of the subchronic and chronic repeat-dose mamma-
lian general toxicology studies discussed next contain one or more
relevant endpoints.
3.1.3. Mammalian general toxicology
Acute/single dose studies were not considered helpful except to
provide some lethal dose information for test species used in stud-
ies that were considered relevant to the WoE analysis of endocrine
responses. There are a number of relevant subchronic and chronic
MTBE studies that report histology of ovarian, uterine, vaginal/cer-
vical, mammary, testis, prostate, seminal vesicle, epididymal, thy-
roid, and pituitary tissues. Where weights of organs were
measured in these studies, they were also considered relevant to
either the estrogen, androgen or thyroid hypotheses. A few of these
studies also reported concentrations of TSH, T4, T3, estradiol and/
or testosterone measured in blood samples. Observations were
extracted from the following subchronic studies, all but one
(Zhou and Ye, 1999) including both female and male animals. A
28-day study was conducted in mice by Chun and Kintigh (1993,
inhalation, 400–8000 ppm). Studies in rats were conducted by
Robinson et al. (1990, gavage, 357–1428 mg/kg/day for 14 days);
IIT Research Institute (1992, gavage, 90–750 mg/kg/day for28 days); Chun and Kintigh (1993, inhalation, 400–8000 ppm for
28 days); and Dong-mei et al. (2009, gavage, 400–1600 mg/kg/
day for 2 or 4 weeks). Longer-term studies, all in rats, consisted
of the following: Greenough et al. (1980, inhalation,
250–1000 ppm for 90 days); Robinson et al. (1990, gavage, 100–
1200 mg/kg/day for 90 days); Lington et al. (1997, inhalation,
800–8000 ppm for 13 weeks); Zhou and Ye (1999, gavage, 200–
1000 mg/kg/day for 13 weeks, males only); and Bermudez et al.
(2012, 13-week and 1-year studies using drinking water exposures
with male rats receiving 37–972 mg/kg BW/day and female rats
receiving 50–1153 mg/kg BW/day as calculated from water
consumption data for each sex and target MTBE concentrations
of 0.5–15 mg/ml in their drinking water). Most of these studies
are consistent in showing no signiﬁcant effect on weights of organs
and histopathology. Potential confounding effects (e.g., signiﬁcant
loss of body weight) were noted that could explain most
inconsistencies. Cell proliferation in testis was examined using
bromodeoxyuridine (BrdU) uptake in one of the 13-week studies
(Bermudez et al., 2012), and no effect was seen. An unpublished
report (Dodd et al., 2010) and other unpublished results from the
study furnished some additional information about a few
endpoints in the 13-week and 1-year studies. For example, there
was no apparent effect of MTBE on TSH, T3, and T4 in either sex,
serum estradiol in the females, serum testosterone in males, or
intratesticular testosterone when analyzed in 28-day samples
taken during the 13-week drinking water study.
The rats in one of these 13-week studies (Lington et al., 1997)
were also given a thorough neurotoxicology evaluation
(Daughtrey et al., 1997). That specialized testing was also of inter-
est in this WoE evaluation since the central nervous system is a
well-recognized primary target of high MTBE exposures. It has also
been recognized that alterations in the brain can be induced by
endocrine active compounds, not only during in utero development
but also possibly in mature neurons (Masuo and Ishido, 2011).
Hypothalamic hormones play essential roles in regulating the
hypothalamic–pituitary–gonadal and hypothalamic–pituitary–
thyroid axes, and other peptides elsewhere in the brain inﬂuence
hypothalamic hormones. Although ultimately this neurotoxicology
evaluation contained no ranked endpoints, the overall results
showing no signiﬁcant effects were considered useful because of
the apical nature of the parameters studied.
Most of these subchronic and chronic general toxicology studies
followed protocols at least similar to standard testing guidelines
current at that time, exceptions being Dong-mei et al. (2009) and
Zhou and Ye (1999). Many additional details about consistency of
individual studies discussed in this section with standard test
protocol expectations can be found in the Supplemental material.
3.1.4. Reproduction, developmental, and carcinogenicity studies
Several reproductive and developmental toxicology studies
have been conducted with MTBE using mice or rats, all using the
inhalation route of exposure and MTBE concentrations as high as
3400 ppm in the mouse studies and 8000 ppm in the rat studies.
Mouse studies were reported in Conaway et al. (1985, teratology,
250–2500 ppm) and Bevan et al. (1997b, development, 300–
3400 ppm). Rat studies were conducted by Conaway et al. (1985,
teratology, 250–2500 ppm); Biles et al. (1987, single generation
reproduction, 300–3400 ppm); Bevan et al. (1997b, development,
1000–8000 ppm); and Bevan et al. (1997a, two-generation repro-
duction, 400–8000 ppm). One teratology study using rabbits was
conducted by Bevan et al. (1997b, 1000–8000 ppm by inhalation).
Although this is an important study insofar as no adverse effects
were observed in offspring of pregnant rabbits exposed to
extremely high concentrations of MTBE, responses in rabbits have
not been evaluated yet to establish any appropriate rankings of
rabbit endpoints in the WoE method used here.
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could reveal some endocrine system dysregulation, or conversely,
if no signiﬁcant effects were seen, indirectly support a conclusion
of no endocrine effect signiﬁcant enough to cause an adverse
response on reproduction or embryo-fetal development. Reproduc-
tive endpoints reported in those studies typically included preg-
nancy index (number of females with conﬁrmed pregnancies/
total number of females used for mating  100), maternal weight
gain, consumption of water and food, and male fertility index
(number of males siring a litter/total number of males used for
mating  100). Adverse developmental responses include:
decreased numbers of corpora lutea or uterine implantations;
increased early or late resorptions, or decreased numbers of live
fetuses observed at C-section; reduced fetal body weight or crown
rump length; altered gender ratio or ano-genital distance; and,
increased percentages of fetuses and litters with external and soft
tissue malformations, or abnormal ossiﬁcation and other varia-
tions. In the absence of other endpoints, however, none of these
endpoints speciﬁcally indicate an endocrine mode of action or dis-
tinguish hormone agonistic from antagonistic behavior. In the end,
very few effects were observed in these studies, and then only at
doses that were maternally toxic. No effect on fragility of oocytes
of female rats was observed after they were dosed with MTBE
added to their drinking water at a concentration of 0.3% (Berger
and Horner, 2003).
These studies sometimes provided more speciﬁc information
about highly ranked endpoints like reproductive organ weights
and/or histology. Most notably, because the two-generation study
in rats reported in Bevan et al. (1997a) exposed the F1 animals
throughout maturation to mating, information relating to pre-/
peripubertal exposures and effects on maturing rodent testis,
uterus, and ovaries could be extracted from this study. Pituitary,
testes, epididymis, prostate and seminal vesicles, and vagina,
uterus, ovaries, and respiratory tract were examined microscopi-
cally from all parent animals (e.g., F0 and F1) of the control and
high dose groups. Livers from F1-animals were also weighed and
those of the control and high dose group were studied microscop-
ically. No histopathological changes in the organs examined were
observed. The F1/ﬁrst generation was exposed in utero, through
maternal milk throughout weaning on PND 28, and then by direct
inhalation starting on PND28. The F1s experienced exposures
through sexual maturation and were then mated to produce an
F2 generation.
Three cancer bioassays with MTBE have been conducted in rats
(Belpoggi et al., 1995; Bird et al., 1997; Dodd et al., 2013) and mice
(Bird et al., 1997). Although these high level apical cancer studies
were not expected to distinguish between the hypotheses being
examined in any deﬁnitive way, an important objective of this
WoE evaluation was to include as many reliable studies as possible
as supporting evidence, if not with speciﬁcally ranked endpoints.
Other than a questionable increase (see Supplemental material
for details) in rat Leydig cell tumors seen in two of these long-term
studies using gavage with 250–1000 mg/kg doses of MTBE
(Belpoggi et al., 1995) or inhalation exposures of 400–8000 ppm
(Bird et al., 1997), no MTBE-related cancers have been seen in
endocrine organs. No increase in rat Leydig cell tumors was found
in a more recent MTBE cancer bioassay using a drinking water
exposure protocol (Dodd et al., 2013). The actual overall calculated
intake of MTBE in the highest dose group in that later bioassay of
MTBE when consumed in drinking water (972 mg/kg BW/day)
was similar to the highest individual bolus gavage doses
(1000 mg kg BW/d, 4/week) used in the study by Belpoggi et al.
(1995). Dodd et al. (2013) also reported some relevant organ
weight measurements made at the end of that 2-year drinking
water exposure, so those elements of the study were included in
the WoE evaluation.3.1.5. Fish and other non-mammalian studies
Most ecotoxicological studies with MTBE are focused on acute
survival effects in short-term tests (ECHA, 2012). Chronic inverte-
brate studies were not considered useful in this assessment for
addressing potential endocrine activity due to the lack of relevant
diagnostic endpoints for estrogen, androgen, and thyroid pathways
and steroidogenesis. Two guideline ﬁsh short-term reproduction
studies (FSTRA), one with fathead minnow (Pimephales promelas)
and one with zebraﬁsh (Danio rerio) are available for the WoE
assessment. The studies followed the US EPA OCSPP 890.1350
and OECD 229 guidelines with the objective to determine if MTBE
might interact with the estrogenic or androgenic hormone axes of
ﬁsh.
In the zebraﬁsh study, exposure of ﬁsh to 0.122 and
3.04 mg MTBE/L had no effect on any of the endpoints measured
except for a statistically signiﬁcant elevation in plasma VTG con-
centrations in male ﬁsh exposed to 3.04 mg/L. This elevation was
marginal (3.4-fold) with individual values within the range nor-
mally observed in adult male zebraﬁsh. Exposure of ﬁsh to
147 mg/L MBTE resulted in a statistically signiﬁcant reduction in
the total number of eggs produced and the number of eggs
produced per female per reproductive day. This reduction in fecun-
dity was accompanied by a statistically signiﬁcant increase in the
incidence of oocyte atresia along with a statistically signiﬁcant
increase in the accumulation of oocyte debris in the
oviduct. Oocyte atresia is a common ﬁnding, even in control ﬁsh,
and its occurrence in this study did not impact the fertility of the
ﬁsh.
In the fathead minnow study, there were no apparent effects on
survival, growth, reproduction, secondary sex characteristics, GSI,
VTG or gonad histopathology in male or female ﬁsh exposed to
MTBE for 21 days to measured concentrations up to 64 mg/L. Based
on the endpoints evaluated, MTBE does not appear to interact with
the estrogenic or androgenic hormone axes of fathead minnows.
These two ﬁsh studies were performed to address ﬁndings of a
non-dose responsive increase in male VTG and the suppression of
sperm mobility in an earlier study by Moreels et al. (2006). Deﬁ-
ciencies in the Moreels et al. study resulted in a Klimisch score of
3 so it is not included in the relevance ranking tables.
A study with the European common brown frog (Rana tempo-
raria) contributed information on metamorphosis and growth to
the WoE assessment (Paulov, 1987). Tadpoles were exposed to
100–10,000 mg MTBE/L. Weights of tadpoles and frogs and timing
of metamorphosis observed in this study were considered rank 3
endpoints because of the lack of coincident information on thyroid
histopathology and speciﬁc measurements on other growth
parameters such as hind limb length.4. Weight of evidence results
Tables 1–8 summarize evidence used in the WoE analysis, iden-
tifying statistically signiﬁcant ﬁndings in ranked endpoints. Some
study reports describe multiple experiments. If a report described
more than one experiment in which a given endpoint was mea-
sured, and the type of result was consistent (i.e., always no effect,
decrease, or increase), then no speciﬁc experiment designation was
shown. However, if results differed between experiments in the
same report then a speciﬁc experiment is indicated. When sufﬁ-
cient information was available as to the expected direction of
change for an endpoint then that was noted in the tables.4.1. Estrogen agonist hypothesis
VTG induction in male ﬁsh and an increase in uterine weight in
a uterotrophic study are two endpoints that are ranked 1 for the
Table 1
Ranked endpoints for relevant MTBE data for the estrogen agonist hypothesis. Endpoint responses compared to controls for each study are noted as having no effect (NE), an
increase (IN), or a decrease (DE). Expected responses of the endpoint to known positives for the hypothesis are noted in the heading with an arrow when available.
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints
FSTRA
VTG " males




NE (Dodd et al., 2013 (rat); Bermudez et al., 2012 (rat); IIT, 1992 (rat);
Robinson et al., 1990 (rat); Biles et al., 1987 (rat); Greenough et al.,
1980 (rat))
DE (Moser et al., 1998 (mouse); Moser et al., 1996 (mouse))
Female rodent studies
Estrous cyclicity







NE (Bermudez et al., 2012 (rat); Okahara, 1999 (mouse); Moser et al.,
1998 (mouse); Lington et al., 1997 (rat); Bevan et al., 1997a (rat);
Moser et al., 1996 (mouse);Chun and Kintigh, 1993 (mouse, rat);
IIT, 1992 (rat); Robinson et al., 1990 (rat); Biles et al., 1987 (rat);
Greenough et al., 1980 (rat))
Blood estradiol
NE (Bermudez et al., 2012 (rat); Moser et al., 1998 (mouse);
Chun and Kintigh, 1993 (mouse))
Mammary tissue histopathology
NE (Lington et al., 1997 (rat); IIT, 1992 (rat); Greenough et al., 1980
(rat))
Uterus weight "
NE (Bermudez et al., 2012 (rat); Bevan et al., 1997a (rat);
Chun and Kintigh, 1993 (mouse, rat); Greenough et al., 1980 (rat))
DE (Moser et al., 1998 (mouse); Moser et al., 1996 (mouse))
Male rodent studies
Testis weight ;
NE (de Peyster et al., 2014 (rat); Dodd et al., 2013 (rat); Bermudez et al.,
2012 (13-wk exposure, rat);Dong-mei et al., 2009 (Expt B/4 wk, rat);
de Peyster et al., 2008 (mouse); Billitti et al., 2005 (mouse); de Peyster
et al., 2003 (rat); Williams et al., 2000 (Expts B and C, rat); Lington
et al., 1997 (rat); Bird et al., 1997 (mouse, rat); IIT, 1992 (rat); Robinson
et al., 1990 (rat), Biles et al., 1987 (rat); Greenough et al., 1980 (rat))
IN (Bermudez et al., 2012 (1 yr exposure, rat); Williams et al., 2000
(Expt A, (rat))
DE (Dong-mei et al., 2009 (Expt A/2 wk, rat))
Uterus histopathology
NE (Bermudez et al., 2012 (rat); Okahara, 1999 (mouse);
Lington et al., 1997 (rat); Bevan et al., 1997a (rat); Moser et al.,
1996 (mouse); Chun and Kintigh, 1993 (mouse, rat); IIT, 1992 (rat);
Greenough et al., 1980 (rat))
IN (Moser et al., 1998 (mouse))
Vaginal/cervical histopathology
DE (Bermudez et al., 2012 (rat));
IN (Moser et al., 1998 (mouse))
ER immunoreactivity in estrogen sensitive tissue
NE (Moser et al., 1998 (mouse))
Testis histopathology
NE (Bermudez et al., 2012 (rat); de Peyster et al., 2008 (mouse);
Billitti et al., 2005 (mouse); Williams et al., 2000 (rat); Zhou and Ye,
1999 (rat); Lington et al., 1997 (rat); Bevan et al., 1997a (rat));
Chun and Kintigh, 1993 (mouse, rat); IIT, 1992 (rat); Robinson et al.,
1990 (rat); Biles et al., 1987 (rat); Greenough et al., 1980 (rat))
IN (Li et al., 2008 (rat))
Oocyte fragility
NE (Berger and Horner, 2003 (rat))
Hepatic estradiol metabolism
IN (Moser et al., 1996 (mouse))
FSTRA
Male tubercle score ;
NE (Mihaich et al., in preparation)
Male gonad histopathology
NE (Mihaich et al., in preparation)
Male behavior
NE (Mihaich et al., in preparation)
ERTA assay
ER agonism
NE (Moser et al., 1998)
Male rodent studies
Prostate weight
NE (de Peyster et al., 2014 (rat); Bermudez et al., 2012 (rat);
Dong-mei et al., 2009 (Expt A/2 wk, rat); de Peyster et al., 2003
(rat); Williams et al., 2000 (rat); Biles et al., 1987 (rat);
Greenough et al., 1980 (rat))
DE (Dong-mei et al., 2009, Expt B/4 wk, rat))
Epididymis histopathology
NE (de Peyster et al., 2008 (mouse); Bevan et al., 1997a (rat);
Lington et al., 1997 (rat); Chun and Kintigh, 1993 (mouse, rat);
IIT, 1992 (rat); Greenough et al., 1980 (rat))
FSTRA
Fecundity
NE (Mihaich et al., in preparation (fathead minnow))
DE (Mihaich et al., in preparation (zebraﬁsh))
Female behavior
NE (Mihaich et al., in preparation)
GSI: ; males, " females
NE (Mihaich et al., in preparation)
Follicular atresia
NE (Mihaich et al., in preparation (fathead minnow))
IN (Mihaich et al., in preparation (zebraﬁsh))
Fertilization success
NE (Mihaich et al., in preparation)
Steroidogenesis assay
Estradiol concentrations
NE (de Peyster et al., 2014)
ER binding assay
Competitive binding
NE (Moser et al., 1998)
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Table 2
Ranked endpoints for relevant MTBE data for the estrogen antagonist hypothesis. Endpoint responses compared to controls for each study are noted as having no effect (NE), an
increase (IN), or a decrease (DE). Expected responses of the endpoint to known positives for the hypothesis are noted in the heading with an arrow when available.
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints





NE (Mihaich et al., in
preparation)
Estrous cyclicity
IN (Moser et al., 1998 (mouse))
Female gonad histopathology
NE (Mihaich et al., in preparation
(fathead minnow))
IN (Mihaich et al., in preparation
(zebraﬁsh))
Blood estradiol
NE (Bermudez et al., 2012 (rat); Moser et al., 1998 (mice); Chun and Kintigh, 1993 (mice))
ERTA Ovarian weight ;
NE (Dodd et al., 2013 (rat); Bermudez et al., 2012 (rat); IIT, 1992 (rat); Robinson et al., 1990 (rat); Biles et al.,
1987 (rat); Greenough et al., 1980 (rat))
DE (Moser et al., 1998 (mouse); Moser et al., 1996 (mouse))
ER antagonism
NE (Moser et al., 1998)
Ovarian histopathology
NE (Bermudez et al., 2012 (rat); Okahara, 1999 (mouse); Moser et al., 1998 (mouse); Lington et al., 1997
(rat); Bevan et al., 1997a (rat); Moser et al., 1996 (mouse); Chun and Kintigh, 1993 (rat); IIT, 1992 (rat);
Robinson et al., 1990 (rat); Biles et al., 1987 (rat); Greenough et al., 1980 (rat))
ER binding assay Mammary tissue histopathology
NE (Lington et al., 1997 (rat); IIT, 1992 (rat); Greenough et al., 1980 (rat))
Competitive binding
NE (Moser et al., 1998)
Uterus weight ;
NE (Bermudez et al., 2012 (rat); Bevan et al., 1997a (rat); Chun and Kintigh, 1993 (mouse, rat); Greenough
et al., 1980 (rat))
DE (Moser et al., 1998 (mouse); Moser et al., 1996 (mouse))
Uterus histopathology
(Bermudez et al., 2012 (rat); Okahara, 1999 (mouse); Lington et al., 1997 (rat); Bevan et al., 1997a (rat);
Moser et al., 1996 (mouse); Chun and Kintigh, 1993 (mouse, rat); IIT, 1992 (rat); Greenough et al., 1980 (rat))
IN (Moser et al., 1998 (mouse))
Vaginal/cervical histopathology
NE (Bermudez et al., 2012 (rat))
IN (Moser et al., 1998 (mouse))
ER immunoreactivity in estrogen sensitive tissue
NE (Moser et al., 1998 (mouse))
Oocyte fragility
NE (Berger and Horner, 2003 (rat))
Hepatic estradiol metabolism
IN (Moser et al., 1996 (mice))
FSTRA
Fecundity
NE (Mihaich et al., in preparation (fathead minnow))
DE (Mihaich et al., in preparation (zebraﬁsh))
Male/female behavior
NE (Mihaich et al., in preparation)
GSI
NE (Mihaich et al., in preparation)
Fertilization success
NE (Mihaich et al., in preparation)
Steroidogenesis assay
Estradiol concentrations
NE (de Peyster et al., 2014)
Aromatase assay
Inhibition
NE (de Peyster et al., 2014)
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to assess the potential for MTBE to interact with the endocrine sys-
tem in fathead minnow (P. promelas) and zebraﬁsh (D. rerio)
(Mihaich et al., in preparation). As this assay screens for distur-
bances in the hypothalamic–pituitary gonadal axis (HPG), it is rel-
evant to six of the eight hypotheses being evaluated. Only
involvement of the thyroid pathway is not addressed in this assay.
While there was a statistically signiﬁcant increase in male VTG at
the mid dose of 3.04 mg/L in the zebraﬁsh study, it was only 3.4-
fold higher than the controls and within the normal historical con-
trol range for the laboratory, so the increase in VTG in the mid-dose
only in the zebraﬁsh study was not considered to be test-substance
related. In the study with fathead minnow, there was no difference
in VTG concentration between control or MTBE-exposed ﬁsh.
No guideline uterotrophic assays are available, although a one
dose, uterotrophic-like study performed in immature mice at ornear the maximum tolerated dose and above the limit dose sug-
gested in the EPA 890.1600 guideline resulted in no change in uter-
ine weight (Okahara, 1999). Uterine weight in cycling adult female
rodents is highly variable (Stoker and Zorilla, 2010) and is there-
fore a rank 3 corroborative endpoint. Uterine weight measure-
ments were reported in a number of studies with MTBE that can
help clarify other ranked endpoints in the WoE, especially when
the ranked study was not performed according to a regulatory
guideline. Studies by Bermudez et al. (2012), Bevan et al.
(1997a), Chun and Kintigh (1993), and Greenough et al. (1980),
using adult rats or mice with a functionally intact HPG axis,
reported no changes in uterine weight compared to control at
any doses used in any of these studies (see Literature Review for
doses used). In contrast, Moser et al. (1996, 1998) both reported
a decrease in uterine weight in mice. Given that for the estrogen
agonist hypothesis a uterine weight increase, not a decrease, would
Table 3
Ranked endpoints for relevant MTBE data for the androgen agonist hypothesis. Endpoint responses compared to controls for each study are noted as having no effect (NE), an
increase (IN), or a decrease (DE). Expected responses of the endpoint to known positives for the hypothesis are noted in the heading with an arrow when available.
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints
Hershberger-like
study






NE (de Peyster et al., 2014 (rat); Dodd et al., 2013 (rat); Bermudez et al.,
2012 (13-wk exposure, rat); Dong-mei et al., 2009 (Expt B/4 wk, rat); de
Peyster et al., 2008 (mouse); Billitti et al., 2005 (mouse); de Peyster et al.,
2003 (rat); Williams et al., 2000 (Expts B and C, rat); Lington et al., 1997
(rat); Bird et al., 1997 (mouse, rat); IIT, 1992 (rat); Robinson et al., 1990
(rat), Biles et al., 1987 (rat); Greenough et al., 1980 (rat))
IN (Bermudez et al., 2012 (1 yr exposure, rat); Williams et al., 2000 (Expt A,
(rat))
DE (Dong-mei et al., 2009 (Expt A/2 wk, rat))
Blood testosterone
NE (de Peyster et al., 2014 (Expt 1, rat); Bermudez et al., 2012 (rat);
de Peyster et al., 2008 (mouse); Billitti et al., 2005 (mouse); de
Peyster et al., 2003 (Expt 1a, Expt 2b, rat); Williams et al., 2000
(Expts A and C, rat))
DE (de Peyster et al., 2014 (Expt 2, rat); de Peyster et al., 2003 (Expt
1a-, Expt 2b, Expt 5 (rat)); Williams et al., 2000 (Expt B, rat))
Li et al., 2008 (Expt A/2 wk, rat))







NE (Bermudez et al., 2012 (rat); de Peyster et al., 2008 (mouse); Billitti et al.,
2005 (mouse); Williams et al., 2000 (rat); Zhou and Ye, 1999 (rat); Lington
et al., 1997 (rat); Bevan et al., 1997a (rat); Chun and Kintigh, 1993 (mouse,
rat); IIT, 1992 (rat); Robinson et al., 1990 (rat); Biles et al., 1987 (rat);
Greenough et al., 1980 (rat))
IN (Li et al., 2008 (rat))
Blood LH
NE (Bermudez et al., 2012 (rat); Li et al., 2008 (B/4 wk, rat);
Williams et al., 2000 (Expts B and C, rat); de Peyster et al., 2003
(Expts 2 and 3, rat))
DE (Williams et al., 2000 (Expt A, rat)); de Peyster et al., 2003 (Expt
5, rat))
IN (Li et al., 2008 (A/2 wk, rat))
FSTRA Epididymides weight
NE (de Peyster et al., 2014 (rat); Dodd et al., 2013 (rat); Bermudez et al.,
2012); de Peyster et al., 2008 (mouse); Li et al., 2008 (rat); de Peyster et al.,
2003 (Expt 1, 2, rat); Williams et al., 2000 (rat); Biles et al., 1987 (rat))
Blood DHT
NE (Williams et al., 2000, (Expt B, rat))







NE (de Peyster et al., 2008 (mouse); Bevan et al., 1997a (rat)); Lington et al.,
1997 (rat); Chun and Kintigh, 1993 (mouse, rat); IIT, 1992 (rat); Greenough
et al., 1980 (rat))
Blood FSH
NE (Bermudez et al., 2012 (rat); Li et al., 2008 (B/4 wk, rat);
Williams et al., 2000 (Expts A and B, rat))
IN (Li et al., 2008 (A/2 wk, rat))
Prostate weight
NE (de Peyster et al., 2014 (rat); Bermudez et al., 2012 (rat); Dong-mei et al.,
2009 (Expt A/2 wk (rat); de Peyster et al., 2003 (rat); Williams et al., 2000
(rat); Biles et al., 1987 (rat); Greenough et al., 1980 (rat))
DE (Dong-mei et al., 2009 (Expt B/4 wk (rat))
Blood prolactin
NE (Bermudez et al., 2012 (rat); de Peyster et al., 2003 (rat);
Williams et al., 2000, rat))
Seminal vesicle weight
NE (de Peyster et al., 2014 (rat); Bermudez et al., 2012 (rat); de Peyster
et al., 2008 (mouse); de Peyster et al., 2003 (rat); Williams et al., 2000 (rat);
Biles et al., 1987 (rat))
Testosterone biotransformation enzymes activity
IN (Williams and Borghoff, 2000, (rat))
FSTRA Liver and testis microsomal aromatase activity
NE (de Peyster et al., 2014 (rat))
DE (de Peyster et al., 2003 (rat))
VTG ; females
NE (Mihaich et al., in preparation)
Aromatase mRNA
NE (de Peyster et al., 2014 (rat liver))
IN (de Peyster et al., 2014 (rat testis))
Gonad histopathology
NE (Mihaich et al., in preparation (fathead minnow))
IN (Mihaich et al., in preparation (zebraﬁsh))
Sperm count
NE (de Peyster et al., 2008 (mouse); (Li et al., 2008 (rat))
Sperm motility
NE (de Peyster et al., 2008 (mouse))
Androgen binding protein mRNA in testis
DE (Li et al., 2008 (rat))
Testosterone measured in testis
NE (de Peyster et al., 2014 (rat);Bermudez et al., 2012 (rat);Wil-
liams et al., 2000 (rat))
Pituitary weight
NE (Bermudez et al., 2012 (rat); de Peyster et al., 2003 (rat);
Williams et al., 2000 (Expt A and C, rat); Greenough et al., 1980
(rat))
IN (Williams et al., 2000 (Expt B, rat))
DE (Moser et al., 1998 (mouse))
Pituitary histopathology
NE (Bermudez et al., 2012 (rat); Lington et al., 1997 (rat); Chun and




NE (Bermudez et al., 2012 (rat); Bevan et al., 1997a (rat); Chun and
Kintigh, 1993 (mouse, rat); Greenough et al., 1980 (rat))
DE (Moser et al., 1998, (mouse); Moser et al., 1996 (mouse))
Ovarian weight
NE (Dodd et al., 2013 (rat); Bermudez et al., 2012 (rat); IIT, 1992
(rat); Robinson et al., 1990; Biles et al., 1987; Greenough et al.,
1980 (rat))
(continued on next page)
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Table 3 (continued)
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints
DE (Moser et al., 1998 (mouse); Moser et al., 1996 (mouse))
Uterine histopathology
NE (Bermudez et al., 2012 (rat); Okahara, 1999 (mouse); Lington
et al., 1997 (rat); Bevan et al., 1997a (rat); Moser et al., 1996
(mouse); Chun and Kintigh, 1993 (mouse, rat); IIT, 1992 (rat);
Greenough et al., 1980 (rat))
IN (Moser et al., 1998 (mouse))
Ovarian histopathology
NE (Bermudez et al., 2012 (rat); Okahara, 1999 (mouse); Moser
et al., 1998 (mouse); Lington et al., 1997 (rat); Bevan et al., 1997a
(rat); Moser et al., 1996 (mouse); Chun and Kintigh, 1993 (mouse,
rat); IIT, 1992 (rat); Robinson et al., 1990 (rat); Biles et al., 1987
(rat); Greenough et al., 1980 (rat))
FSTRA
Fecundity
NE (Mihaich et al., in preparation (fathead minnow))
DE (Mihaich et al., in preparation (zebraﬁsh))
Behavior
NE (Mihaich et al., in preparation)
GSI
NE (Mihaich et al., in preparation)
Fertilization success
NE (Mihaich et al., in preparation)
Steroidogenesis assay
Testosterone concentrations
NE (de Peyster et al., 2014)
Aromatase assay
Inhibition
NE (de Peyster et al., 2014)
AR binding assay
Competitive binding
NE (de Peyster et al., 2014)
a NE in Expt 1 when sampled on Day 14, by tail vein, or on Day 28 at necropsy, both sampling times 12–20 h after the ﬁnal MTBE dose, but DE in the same Expt 1 when
blood was sampled by tail vein 4–5 h after the ﬁrst MTBE dose.
b NE in Expt 2 when sampled on Day 14 by tail vein just prior to dosing, but DE on Day 28 at necropsy 16–20 h after ﬁnal MTBE dose.
358 A. de Peyster, E. Mihaich / Regulatory Toxicology and Pharmacology 69 (2014) 348–370be expected, the results from many studies provide corroborative
evidence for the preliminary ﬁnding that the estrogen agonist
hypothesis is not supported. Similarly, there was no change in
ovarian weight, a rank 2 endpoint, compared to controls in a num-
ber of studies with rats (Dodd et al., 2013; Bermudez et al., 2012;
IIT Research Institute, 1992; Robinson et al., 1990; Biles et al.,
1987; Greenough et al., 1980) although there was a decrease in
ovarian weight in mice in the studies by Moser et al. (1996,
1998). Ovarian weight would be expected to decrease with expo-
sure to estrogenic compounds (Stoker and Zorrilla, 2010; Biegel
et al., 1998). However, the decrease in uterine weight in the same
species (Moser et al., 1996, 1998) when an increase would be
expected with an estrogen agonist, suggests that MTBE is not con-
sistently exhibiting estrogenic potential in mice. There were no
ovarian histopathological changes noted when compared to con-
trols with either female rats or mice (Table 1). The only histopa-
thological ﬁnding reported in female estrogen-dependent
reproductive tissue was a description of mouse uterus and vagina
being similar in appearance to what would be expected in ovariec-
tomized mice (Moser et al., 1998). This ﬁnding was not mentioned
in an earlier study of comparable duration and high inhalation dose
levels (up to 8000 ppm) using the same CD-1 strain of mouse
(Chun and Kintigh, 1993).
Testis weights and histopathology endpoints are also rank 2. For
the estrogen agonist hypothesis, a decrease in testis weight would
be expected if the chemical is acting like an estrogen (Cook et al.,
1998). Many measurements of weight of the testes have been
made in MTBE experiments, some with gavage doses as high as
1000–1600 mg/kg BW/day in subchronic studies and 1000 mg/
kg BW/day orally or 8000 ppm by inhalation in studies lasting up
to 1–2 years. Results from 14 studies reveal no effect (Table 1).Only three studies indicated weight changes compared to controls
in testis and two of them reported an increase in relative weight,
rather than a decrease. Bermudez et al. (2012) reported an increase
in left testis weight:BW ratio in the two higher dose groups with
no change in the same ratio on the right side, no change in absolute
weights of either testis, and no testis histopathology ﬁndings after
1 year of exposure to MTBE in drinking water where the highest
target concentration used was 15 mg MTBE/ml (calculated later
to be 972 mg/kg BW/day). Signiﬁcantly reduced body weights
were observed in all MTBE-treated groups in that experiment, so
this ﬁnding could simply be due to the comparatively lower body
weights observed in these dose groups. In the study by Williams
et al. (2000) in which testis:body weight (BW) ratio was
also increased this was seen only at the highest gavage dose
(1500 mg/kg/day). This ﬁnding could also simply be due to the
comparatively lower body weights observed in that dose group,
an interpretation supported by the absolute testis weights in that
experiment that were no different from controls. The interpreta-
tion in both experiments of a possible BW-driven difference in
ratios is a reasonable alternative to an effect on the testis itself.
In a third study (Dong-mei et al., 2009), investigators gavaging
with doses up to 1600 mg/kg BW/day reported a decrease in tes-
tis:BW ratio seen in a 2-week experiment (experiment A) but not
in a companion 4-week experiment (experiment B) and, at
2 weeks, the decrease was of the same magnitude (11–12%) in all
MTBE dose groups. The signiﬁcance of effect is questionable when
they are not consistent across similar experiments and the magni-
tude does not increase or decrease as doses increase. The lack of
consistency and the equivocal nature of the interpretations is
evidence that MTBE does not alter testis weights in rodents, even
when administered at high doses.
Table 4
Ranked endpoints for relevant MTBE data for the androgen antagonist hypothesis. Endpoint responses compared to controls for each study are noted as having no effect (NE), an
increase (IN), or a decrease (DE). Expected responses of the endpoint to known positives for the hypothesis are noted in the heading with an arrow when available.
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints
Hershberger-like study Male rodent studies Male rodent studies
Prostate weight
NE (de Peyster et al., 2003 (Expt 3, rat))
Testis weight
NE (de Peyster et al., 2014 (rat); (Dodd et al., 2013
(rat); Bermudez et al., 2012 (13 wk, rat); Dong-mei
et al., 2009 (Expt B/4 wk, rat); de Peyster et al., 2008
(mouse); Billitti et al., 2005 (mouse); de Peyster
et al., 2003 (rat); Williams et al., 2000 (Expts B and
C, rat); Lington et al., 1997(rat); Bird et al., 1997
(mouse, rat); IIT, 1992 (rat); Robinson et al., 1990
(rat), Biles et al., 1987 (rat); Greenough et al., 1980
(rat))
IN (Bermudez et al., 2012 (1 yr exposure, rat);
Williams et al., 2000 (Expt A, (rat))
DE (Dong-mei et al., 2009 (Expt A/2 wk, rat))
Blood testosterone
NE (de Peyster et al., 2014 (Expt 1, rat); Bermudez
et al., 2012 (rat); de Peyster et al., 2008 (mouse);
Billitti et al., 2005 (mouse); de Peyster et al., 2003
(Expt 1a, Expt 2b, rat); Williams et al., 2000 (Expts A
and C, rat))
DE (de Peyster et al., 2014 (Expt 2, rat); de Peyster
et al., 2003 (Expt 1a-, Expt 2b, Expt 5 (rat)); Williams
et al., 2000 (Expt B, rat); Li et al., 2008 (Expt A/
2 week, rat))
IN (Li et al., 2008 (Expt B/4 week, rat))
Seminal vesicle weight
NE (de Peyster et al., 2003 (Expt 3, rat))
Testes histopathology
NE (Bermudez et al., 2012 (rat); de Peyster et al.,
2008 (mouse); Billitti et al., 2005 (mouse); Williams
et al., 2000 (rat); Zhou and Ye, 1999 (rat); Lington
et al., 1997 (rat); Bevan et al., 1997a (rat)); Chun
and Kintigh, 1993 (mouse, rat); IIT, 1992 (rat);
Robinson et al., 1990 (rat); Biles et al., 1987 (rat);
Greenough et al., 1980 (rat))
IN (Li et al., 2008 (rat))
Blood LH
NE (Bermudez et al., 2012 (rat); Li et al., 2008 (Expt
B/4 wk, rat); Williams et al., 2000 (Expts B and C,
rat); de Peyster et al., 2003 (Expts 2 and 3, rat))
DE (Williams et al., 2000 (Expt A, rat); de Peyster
et al., 2003 (Expt 5, rat))
IN (Li et al., 2008 (Expt A/2 wk, rat))
Epididymides weight
NE (Bermudez et al., 2012); de Peyster et al., 2008
(mice); Li et al., 2008 (rat); de Peyster et al., 2003
(rat); Williams et al., 2000 (rat); Biles et al., 1987
(rat))
Blood DHT
NE (Williams et al., 2000, (Expt B, rat))
DE (Williams et al., 2000, (Expt A, rat))
Epididymides histopathology
NE (de Peyster et al., 2008 (mouse); Bevan et al.,
1997a (rat); Lington et al., 1997 (rat); Chun and
Kintigh 1993 (mouse, rat); IIT, 1992 (rat);
Greenough et al., 1980 (rat))
Blood FSH
NE (Bermudez et al., 2012 (rat); Li et al., 2008 (Expt
B/4 wk, rat); Williams et al., 2000 (Expts A and B,
rat))
IN (Li et al., 2008 (Expt A/2 wk, rat))
Prostate weight
NE (de Peyster et al., 2014 (rat); Bermudez et al.,
2012 (rat); Dong-mei et al., 2009 (Expt A/2 wk (rat);
de Peyster et al., 2003 (rat); Williams et al., 2000
(rat); Biles et al., 1987 (rat); Greenough et al., 1980
(rat))
DE (Dong-mei et al., 2009 (Expt B/4 wk (rat))
Blood prolactin
NE (Bermudez et al., 2012 (rat); de Peyster et al.,
2003 (rat); Williams et al., 2000, (rat))
Seminal vesicle weight
NE (de Peyster et al., 2014 (rat); Bermudez et al.,
2012 (rat); de Peyster et al., 2008 (mouse); de
Peyster et al., 2003 (rat); Williams et al., 2000 (rat);
Biles et al., 1987 (rat))
Testosterone biotransformation enzymes activity
IN (Williams and Borghoff, 2000 (rat))
FSTRA Liver and testis microsomal aromatase activity
NE (de Peyster et al., 2014 (rat))
DE (de Peyster et al., 2003 (rat))
VTG " females
NE (Mihaich et al., in preparation)
Aromatase mRNA
NE (de Peyster et al., 2014 (rat liver))
IN (de Peyster et al., 2014 (Exp 2 – rat testis))
Male secondary sex characteristics ;
NE (Mihaich et al., in preparation)
Sperm count
NE (de Peyster et al., 2008 (mouse); Li et al., 2008
(rat))
Gonad histopathology
NE (Mihaich et al., in preparation (fathead min-
now))
IN (Mihaich et al., in preparation (zebraﬁsh))
Sperm motility
NE (de Peyster et al., 2008 (mouse))
Androgen binding protein mRNA in testis
DE (Li et al., 2008 (rat))
Testosterone measured in testis
NE (de Peyster et al., 2014 (rat); Bermudez et al.,
2012 (rat); Williams et al., 2000 (rat))
Pituitary weight
NE (Bermudez et al., 2012 (rat); Williams et al.,
2000 (Expts A and C, rat))
IN (Williams et al., 2000 (Expt B, rat))
DE (de Peyster et al., 2003 (rat); Moser et al., 1998
(continued on next page)
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Table 4 (continued)
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints
(mouse))
Pituitary histopathology
NE (Bermudez et al., 2012 (rat); Lington et al., 1997
(rat); Chun and Kintigh, 1993 (mouse, rat); IIT, 1992
(rat); Greenough et al., 1980 (rat))
FSTRA
Fecundity
NE (Mihaich et al., in preparation (fathead min-
now))
DE (Mihaich et al., in preparation (zebraﬁsh))
Behavior
NE (Mihaich et al., in preparation)
GSI
NE (Mihaich et al., in preparation)
Fertilization success
NE (Mihaich et al., in preparation)
Steroidogenesis assay
Testosterone concentrations
NE (de Peyster et al., 2014)
AR binding assay
Competitive binding
NE (de Peyster et al., 2014)
a NE in Expt 1 when sampled on Day 14, by tail vein, or on Day 28 at necropsy, both sampling times 12–20 h after the ﬁnal MTBE dose, but DE in the same Expt 1 when
blood was sampled by tail vein 4–5 h after the ﬁrst MTBE dose.
b NE in Expt 2 when sampled on Day 14 by tail vein just prior to dosing, but DE on Day 28 at necropsy 16–20 h after ﬁnal MTBE dose.
Table 5
Ranked endpoints for relevant MTBE data for the thyroid agonist hypothesis. Endpoint responses compared to controls for each study are noted as having no effect (NE), an
increase (IN), or a decrease (DE). Expected responses of the endpoint to known positives for the hypothesis are noted in the heading with an arrow when available.
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints
Male rodent studies Male rodent studies




NE (Dodd et al., 2013 (rat); Bermudez et al., 2012 (13 wk, rat); Chun
and Kintigh, 1993 (mouse, rat); Greenough et al., 1980 (rat))
IN (de Peyster et al., 2003 (rat))
DE (Bermudez et al., 2012 (1 yr, rat))
Pituitary weight
NE (Bermudez et al., 2012 (rat); de Peyster et al., 2003 (rat); Williams
et al., 2000 (Expts A and C, rat); Greenough et al., 1980 (rat))
IN (Williams et al., 2000 (Expt B, rat))
DE (Moser et al., 1998 (mouse))
Blood T4
NE (Bermudez et al., 2012 (27 wk and 1-yr, rat); Dodd et al., 2010
(rat); Williams et al., 2000 (rat))
IN (Chun and Kintigh, 1993 (mouse))
DE (Bermudez et al., 2012a (rat))
Pituitary histopathology
NE (Bermudez et al., 2012 (rat); Lington et al., 1997 (rat); Chun and
Kintigh, 1993 (mouse, rat); IIT, 1992 (rat); Greenough et al., 1980 (rat))
Blood T3
NE (Bermudez et al., 2012, rat); Dodd et al., 2010 (rat); Williams
et al., 2000 (Expt B, rat); Chun and Kintigh, 1993 (mouse))
DE (Williams et al., 2000 (Expt A, rat))
Thyroid histopathology
NE (Bermudez et al., 2012 (1 yr); Lington et al., 1997 (rat); Chun and
Kintigh, 1993 (mouse); IIT, 1992 (rat); Greenough et al., 1980 (rat))
Blood TSH
NE (Bermudez et al., 2012 (rat); Dodd et al., 2010 (rat); Williams
et al., 2000 (rat))
IN (Chun and Kintigh, 1993 (mouse))
Female rodent studies
Female rodent studies Pituitary weight
NE (Bermudez et al., 2012 (rat); Greenough et al., 1980 (rat))
DE (Moser et al., 1998 (mouse))
Thyroid weight
NE (Dodd et al., 2013 (rat); Bermudez et al., 2012 (rat); Chun and
Kintigh, 1993 (mouse, rat); Greenough et al., 1980 (rat))
Pituitary histopathology
NE (Bermudez et al., 2012 (rat); Lington et al., 1997 (rat); Chun and
Kintigh, 1993 (mouse, rat); IIT, 1992 (rat); Greenough et al., 1980 (rat))
Blood T4
NE (Bermudez et al., 2012 (rat); Dodd et al., 2010 (rat); Chun and
Kintigh, 1993 (mouse))
Thyroid histopathology
NE (Bermudez et al., 2012 (1 yr); Lington et al., 1997 (rat); Chun and
Kintigh, 1993 (mouse); IIT, 1992 (rat); Greenough et al., 1980 (rat))
Blood T3




NE (Bermudez et al., 2012 (rat); Dodd et al., 2010 (rat); Chun and
Kintigh, 1993 (mouse))
Frog metamorphosis rate and weight
IN (Paulov, 1987 (Rana temporaria))
a High dose group statistically lower than controls in cardiac blood samples from ﬁve males per concentration at day 28 of the 13-week exposure experiment. TSH and T3
were no different from controls. (No organ weights or histopathology measurements were taken at that time.)
360 A. de Peyster, E. Mihaich / Regulatory Toxicology and Pharmacology 69 (2014) 348–370Thirteen studies have evaluated testicular histopathology, with
12 studies reporting no effect. Only one, Li et al. (2008), reported an
increase in less compact cells with some shedding of cellular
material in seminiferous epithelium in rats. Unfortunately, testis
weight was not assessed in this study and there is no indicationof either severity scores or number of rats with this ﬁnding, which
rate this aspect of the study a Klimisch 4. Other than these few
ﬁndings, there were no changes compared to controls in testis
weight or histopathology in many studies with both rats and mice
(Table 1).
Table 6
Ranked endpoints for relevant MTBE data for the thyroid antagonist hypothesis. Endpoint responses compared to controls for each study are noted as having no effect (NE), an
increase (IN), or a decrease (DE). Expected responses of the endpoint to known positives for the hypothesis are noted in the heading with an arrow when available.
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints
Male rodent studies Male rodent studies Male rodent studies
Thyroid weight
NE (Dodd et al., 2013 (rat); Bermudez et al., 2012
(13 wk, rat); Chun and Kintigh, 1993 (mouse, rat)
Greenough et al., 1980 (rat))
IN (de Peyster et al., 2003 (rat))
DE (Bermudez et al., 2012 (1 yr, rat))
Blood T4
NE (Bermudez et al., 2012 (27 wk and 1-yr, rat); Dodd
et al., 2010 (rat); Williams et al., 2000 (rat))
IN (Chun and Kintigh, 1993 (mouse))
DE (Bermudez et al., 2012a (rat))
Pituitary weight
NE (Bermudez et al., 2012 (rat); de Peyster et al.,
2003 (rat); Williams et al., 2000 (Expts A and C, rat);
Greenough et al., 1980 (rat))
IN (Williams et al., 2000 (Expt B, rat))
DE (Moser et al., 1998 (mouse))
Thyroid histopathology
NE (Bermudez et al., 2012 (1 yr, rat); Lington et al.,
1997 (rat); Chun and Kintigh, 1993 (mouse); IIT,
1992 (rat); Greenough et al., 1980 (rat))
Blood T3
NE (Bermudez et al., 2012 (rat); Dodd et al., 2010 (rat);
Williams et al., 2000 (Expt B, rat); Chun and Kintigh,
1993 (mouse))
DE (Williams et al., 2000 (Expt A, rat))
Pituitary histopathology
NE (Bermudez et al., 2012 (rat); Lington et al., 1997
(rat); Chun and Kintigh, 1993 (mouse, rat); IIT, 1992
(rat); Greenough et al., 1980 (rat))
Female rodent studies Blood TSH
NE (Bermudez et al., 2012 (rat); Dodd et al., 2010 (rat);
Williams et al., 2000 (rat))
IN (Chun and Kintigh, 1993 (mouse))
Female rodent studies
Thyroid weight
NE (Dodd et al., 2013 (rat); Chun and Kintigh, 1993
(mouse, rat); Greenough et al., 1980 (rat))
Female rodent studies Pituitary weight
NE (Bermudez et al., 2012 (rat); Greenough et al.,
1980 (rat))
DE (Moser et al., 1998 (mouse))
Thyroid histopathology
NE (Chun and Kintigh, 1993 (mouse); IIT, 1992
(rat); Greenough et al., 1980 (rat))
Ovarian weight ;
NE (Dodd et al., 2013 (rat); Bermudez et al., 2012 (rat);
IIT, 1992 (rat); Robinson et al., 1990 (rat); Biles et al.,
1987 (rat); Greenough et al., 1980 (rat))
DE (Moser et al., 1998 (mouse); Moser et al., 1996
(mouse))
Pituitary histopathology
NE (Bermudez et al., 2012 (rat); Lington et al., 1997
(rat); Chun and Kintigh, 1993 (mouse, rat); IIT, 1992
(rat); Greenough et al., 1980 (rat))
Blood TSH
NE (Bermudez et al., 2012 (rat); Dodd et al., 2010 (rat);
Chun and Kintigh, 1993 (mouse))
Amphibian study
Blood T4
NE (Bermudez et al., 2012 (rat); Dodd et al., 2010 (rat);
Chun and Kintigh, 1993 (mouse))
Frog metamorphosis rate and weight
IN (Paulov, 1987 (Rana temporaria))
Blood T3
NE (Bermudez et al., 2012 (rat); Dodd et al., 2010 (rat);
Chun and Kintigh, 1993 (mouse))
a High dose group statistically lower than controls in cardiac blood samples from ﬁve males per concentration at day 28 of the 13-week exposure experiment. TSH and T3
were no different from controls. No organ weights or histopathology measurements were taken at that time.
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the zebraﬁsh and fathead minnow studies there were no changes
in male gonad histopathology or male behavior (Mihaich et al., in
preparation). Tubercles are only assessed in male fathead minnow
and there were no changes in the tubercle score in ﬁsh exposed to
up to 62 mgMTBE/L compared to controls.
The ﬁnal rank 2 study available is the estrogen receptor tran-
scriptional activation study (ERTA) which measures the ability of
a chemical to bind to the ER and activate transcription (Table 1).
The ERTA is considered a rank 2 study while the estrogen receptor
binding (ERB) screen is a rank 3 because the ERTA can distinguish
between agonist and antagonist responses while the ERB currently
is not validated to differentiate the responses (Borgert et al., 2014).
MTBE did not exhibit ER agonism in the ERTA study (Moser et al.,
1998).
For the most part, all rank 3 endpoints including estradiol
concentrations in serum of both female mice and rats and in the
in vitro steroidogenesis assay, prostate weights, and the ERB exhib-
ited no differences compared to controls. Estrous and non-estrous
stages were both lengthened in one study but this occurred at a
dose where there was a signiﬁcantly decreased body weight gain
(Moser et al., 1998). The absence of histopathology ﬁndings in rat
mammary tissue (Lington et al., 1997; IIT Research Institute,
1992; Greenough et al., 1980) lends further support that MTBE is
not acting as an estrogen agonist.
In the ﬁsh model, while the increase in VTG in male zebraﬁsh is
a rank 1 endpoint suggestive of an estrogenic response, it conﬂicts
with the decrease in fecundity, a potentially androgenic response ifcontrolled by a hormonal MoA. With only minor and non-consis-
tent ranks 2 and 3 responses in high dose rodent and ﬁsh (rank 3
only) studies there is no clear supportive evidence of a direct ago-
nist effect on the estrogen pathway.
4.2. Estrogen antagonist hypothesis
As described in Borgert et al. (2014), none of the endpoints in
the current US EDSP Tier 1 screens are considered sufﬁciently sen-
sitive and speciﬁc to assign them rank 1 status, although it was
noted that the antagonist mode of the uterotrophic study would
be so ranked when validated. Okahara (1999) did evaluate both
agonist and antagonist responses in an uterotrophic-like bioassay
(see Supplemental material for additional information). Immature
CD-1 mice were exposed to MTBE with/without 17b-estradiol. To
test estrogen antagonist behavior, the MTBE+17b-estradiol
responses were compared to a 17b-estradiol-only control. The
MTBE treatment in these experiments produced no statistically
signiﬁcant effects on immature mouse uterus or ovary. A positive
antagonist control, clomiphene citrate, was also employed in the
Okahara study. While uterine weight was not impacted by the
positive control, clomiphene citrate administered to mice also trea-
ted with 17b-estradiol did cause a statistically signiﬁcant decrease
relative to the 17b-estradiol-only control group in uterine peroxi-
dase activity also measured in that study. Uterine peroxidase is
an enzyme that responds to estrogenic/antiestrogenic effects of
chemicals (Lyttle and DeSombre, 1977). MTBE administered to
mice also treated with 17b-estradiol did not cause a statistically
Table 7
Ranked endpoints for relevant MTBE data for the steroidogenesis induction hypothesis. Endpoint responses compared to controls for each study are noted as having no effect (NE),
an increase (IN), or a decrease (DE). Expected responses of the endpoint to known positives for the hypothesis are noted in the heading with an arrow when available.








NE (de Peyster et al.,
2014 (rat))
Blood testosterone
NE (de Peyster et al., 2014 (Expt 1, rat); Bermudez et al., 2012 (rat); de Peyster et al., 2008 (mouse); de Peyster
et al., 2003 (Expt 1a, Expt 2b, rat); Williams et al., 2000 (Expts A and C, rat))
DE (de Peyster et al., 2014 (Expt 2, rat); de Peyster et al., 2003 (Expt 1a-, Expt 2b, Expt 5, rat); Williams et al., 2000
(Expt B, rat);
Li et al., 2008 (Expt A/2 week, rat))
IN (Li et al., 2008 (Expt B/4 week, rat))
Testosterone
concentrations
NE (de Peyster et al.,
2014 (rat))
Blood estradiol
NE: (de Peyster et al., 2014 (rat); de Peyster et al., 2008 (mouse))
IN (de Peyster et al., 2003 (rat))
Liver and testis microsomal aromatase activity
NE (de Peyster et al., 2014 (rat))
DE (de Peyster et al., 2003 (rat))
Aromatase mRNA
NE (de Peyster et al., 2014 (rat liver))
IN (de Peyster et al., 2014 (rat testis))
Testosterone measured in testis
NE (de Peyster et al., 2014 (rat);Bermudez et al., 2012 (rat);Williams et al., 2000 (rat))
Female rodent studies
Blood estradiol
NE (Moser et al., 1998 (mouse); Chun and Kintigh, 1993 (mice))
a NE in Expt 1 when sampled on Day 14, by tail vein, or on Day 28 at necropsy, both sampling times 12–20 h after the ﬁnal MTBE dose, but DE in the same Expt 1 when
blood sampled by tail vein 4–5 h after the ﬁrst MTBE dose.
b NE in Expt 2 when sampled on Day 14 by tail vein just prior to dosing, but DE on Day 28 at necropsy 16–20 h after ﬁnal MTBE dose.
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17b-estradiol-only control group, indicating lack of estrogen antag-
onist behavior of MTBE.
MTBE did not decrease female VTG in either fathead minnow or
zebraﬁsh compared to controls in the two FSTRA studies (Table 2).
There was an increase in oocyte atresia, along with a reduction in
fecundity, in the zebraﬁsh study however, there were no impacts
on fertilization success of the ﬁsh in this study. Oocyte atresia is
a common ﬁnding in control ﬁsh (McCormick et al., 1989;
Hunter and Macewicz, 1985; Henderson, 1963) and is often a
result of general toxicity or stress unrelated to a sex hormone path-
way MoA (Clearwater and Pankhurst, 1997; Milla et al., 2009). No
female gonad histopathology differences from controls were iden-
tiﬁed in the fathead minnow study that used slightly lower doses
than in the zebraﬁsh study.
While the ERB was considered a rank 3 endpoint for the estro-
gen agonist hypothesis, it is a rank 2 for the antagonist hypothesis
because intrinsic activity is not required to evaluate an estrogen
antagonist (Borgert et al., 2014), as binding alone is sufﬁcient.
MTBE did not exhibit any difference compared to controls in the
ERB or the ERTA experiments (Moser et al., 1998) (Table 2).
Estrogen antagonists would be expected to decrease uterine
weights (Ashby et al., 2002). However, uterine weights are extre-
mely variable in cycling rodents (Stoker and Zorrilla, 2010) so it
is considered a rank 3 endpoint that would need corroboration of
rank 1 or 2 endpoints to be meaningful. Estrogen antagonists
would also be expected to decrease ovary weights and cause ovary
atrophy (Borgert et al., 2014). While there were no differences
compared to controls in uterus or ovary weights in rats (Dodd
et al., 2013; Bermudez et al., 2012; Bevan et al., 1997a; Chun and
Kintigh, 1993; IIT Research Institute, 1992; Robinson et al., 1990;
Biles et al., 1987; Greenough et al., 1980), and in one general tox-
icology study that reported on mouse uterus weights (Chun and
Kintigh, 1993), there were decreases in uterine and ovary weights
seen in two studies with mice (Moser et al., 1996, 1998) (Table 2).
Moser et al. (1996) found a twofold increase in the rate of 17b-
estradiol metabolism in hepatocytes isolated from mice treatedwith MTBE at 1800 mg/kg BW/day for 3 days, and Moser et al.
(1998) reported that the uteri of mice exposed by inhalation to
MTBE at 8000 ppm resembled what would be expected in overiec-
tomized mice, which suggests low estrogen concentrations. A
reduction in circulating estradiol could also be responsible for
the increase in estrous cycle length that was noted in the Moser
et al. (1998) study, as could MTBE-induced decreases in body
weight gain and stress (Moser et al., 1998; Everds et al., 2013).
However, serum estradiol concentrations, a rank 3 endpoint, were
unchanged compared to controls. Otherwise, there were no uterine
or ovarian histopthological changes noted when compared to con-
trols with either female rats or mice (Table 2).
Other rank 3 endpoints from two in vitro studies targeting the
steroidogenic pathway assess endpoints that could be relevant to
estrogen antagonists. Aromatase, the enzyme responsible for the
conversion of androgens to estrogens, was not inhibited in the
aromatase assay and estradiol concentrations were not different
from control in the steroidogenesis assay (de Peyster et al., 2014)
(Table 2).
In summary, rank 1 uterus weight was not decreased compared
to controls and the rank 2 endpoints in the FSTRA, ERTA, and ER
binding were also not impacted by exposure to MTBE, except as
noted for the zebraﬁsh. While the results of the ranks 1 and 2 end-
point assessment are sufﬁcient to conclude a lack of potential for
the estrogen antagonist hypothesis, the majority of the rank 3 end-
points are also negative, thus providing additional corroboration
for no direct antagonist effect on the estrogen pathway.
4.3. Androgen agonist hypothesis
Accessory sex organ weight in a Hershberger study and sec-
ondary sex characteristics (e.g., tubercles) in ﬁsh are rank 1 end-
points for the androgen agonist hypothesis. In the US EDSP, the
Hershberger study is used to assess effects on accessory sex
organs in the castrated male peripubertal rat (US EPA, 2009a)
by measuring the weight of ﬁve androgen-dependent tissues.
An increase in weight compared to controls in two of the ﬁve is
Table 8
Ranked endpoints for relevant MTBE data for the steroidogenesis inhibition hypothesis. Endpoint responses compared to controls for each study are noted as having no effect
(NE), an increase (IN), or a decrease (DE). Expected responses of the endpoint to known positives for the hypothesis are noted in the heading with an arrow when available.
Rank 1 endpoints Rank 2 endpoints Rank 3 endpoints





NE (de Peyster et al.,
2014 (rat))
Inhibition
NE (de Peyster et al., 2014 (rat))
Testosterone
concentrations




NE (Mihaich et al., in preparation (fathead minnow))
DE (Mihaich et al., in preparation (zebraﬁsh))
VTG ; females
NE (Mihaich et al., in
preparation)
Behavior
NE (Mihaich et al., in preparation)
Male gonad
histopathology
NE (Mihaich et al., in
preparation)
GSI
NE (Mihaich et al., in preparation)
Fertilization success
NE (Mihaich et al., in preparation)
Male rodent studies
Blood testosterone
NE (de Peyster et al., 2014 (Expt 1, rat); Bermudez et al., 2012 (rat); de Peyster et al., 2008 (mouse); de Peyster et al., 2003
(Expt 1a, Expt 2b, rat); Williams et al., 2000 (Expts A and C, rat))
DE (de Peyster et al., 2014 (Expt 2, rat); de Peyster et al., 2003 (Expt 1a-, Expt 2b, Expt 5, rat); Williams et al., 2000 (Expt B,
rat);
Li et al., 2008 (Expt A/2 week, rat))
IN (Li et al., 2009 (Expt B/4 week, rat))
Blood estradiol
NE: (de Peyster et al., 2014 (rat); de Peyster et al., 2008 (mouse))
IN (de Peyster et al., 2003 (rat))
Testis weight
NE (de Peyster et al., 2014 (rat); Dodd et al., 2013 (rat); Bermudez et al., 2012 (13-wk exposure, rat); Dong-mei et al.,
2009 (Expt B/4 wk, rat); de Peyster et al., 2008 (mouse); Billitti et al., 2005 (mouse); de Peyster et al., 2003 (rat); Williams
et al., 2000 (Expts B and C, rat); Lington et al., 1997(rat); Bird et al., 1997 (mouse, rat); IIT, 1992 (rat); Robinson et al.,
1990 (rat), Biles et al., 1987 (rat); Greenough et al., 1980 (rat))
IN (Bermudez et al., 2012 (1 yr exposure, rat); Williams et al., 2000 (Expt A, rat))
DE (Dong-mei et al., 2009 (Expt A/2 wk, rat))
Prostate weight
NE (de Peyster et al., 2014 (rat); Bermudez et al., 2012 (rat); Dong-mei et al., 2009 (Expt A/2 wk, rat); de Peyster et al.,
2003 (rat); Williams et al., 2000 (rat); Biles et al., 1987 (rat); Greenough et al., 1980 (rat))
DE (Dong-mei et al., 2009 (Expt B/4 wk (rat))
Seminal vesicle weight
NE (de Peyster et al., 2014 (rat); Bermudez et al., 2012 (rat); de Peyster et al., 2008 (mouse); de Peyster et al., 2003 (rat);
Williams et al., 2000 (rat); Biles et al., 1987 (rat))
Liver and testis microsomal aromatase activity
NE (de Peyster et al., 2014 (rat))
DE (de Peyster et al., 2003 (rat))
Aromatase mRNA
NE (de Peyster et al., 2014 (rat liver))
IN (de Peyster et al., 2014 (rat testis))
Testosterone measured in testis
NE (de Peyster et al., 2014 (rat); Bermudez et al., 2012 (rat); Williams et al., 2000 (rat))
a NE in Expt 1 when sampled on Day 14, by tail vein, or on Day 28 at necropsy, both sampling times 12–20 h after the ﬁnal MTBE dose, but DE in the same Expt 1 when
blood was sampled by tail vein 4–5 h after the ﬁrst MTBE dose.
b NE in Expt 2 when sampled on Day 14 by tail vein just prior to dosing, but DE on Day 28 at necropsy 16–20 h after ﬁnal MTBE dose.
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line. The study by de Peyster et al. (2003) was performed in a
similar manner to a Hershberger method, although weights of
only two androgen-sensitive tissues, prostate and seminal vesi-
cles, were evaluated. In that study, MTBE did not increase the
weights of prostate or seminal vesiscles in rats not supplemented
with testosterone propionate. Further corroboration of no impacts
on prostate and seminal vesicles in both rats and mice comes
from the results of a number of studies with endpoints consid-
ered as rank 2 (de Peyster et al., 2014, 2008, 2003; Bermudez
et al., 2012; Williams et al., 2000; Biles et al., 1987; Greenough
et al., 1980) (Table 3). An androgen agonist would be expected
to increase prostate weight – not decrease it – a ﬁnding reportedby one rat study using a very high dose of MTBE (1600 mg/kg
BW/day) (Dong-mei et al., 2009).
Increases in the presence of tubercles in female fathead minnow
is speciﬁcally linked to positive activity in the androgen pathway
(Ankley et al., 2003; Ankley and Gray, 2013). In the fathead min-
now FSTRA, no tubercles were present on female ﬁsh suggesting
that MTBE is not androgenic in that test system.
In addition to prostate and seminal vesicle weights already dis-
cussed earlier, other rank 2 endpoints include testis and epididy-
mal weights and histopathology, female VTG and gonadal
histopathology in ﬁsh, and AR competitive binding. Testis weight
and histopathology were largely unaffected in both rats and mice
after exposure to MTBE (Table 3). There were two studies that
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not absolute weight was increased coinciding with a signiﬁcant
reduction in body weight gain indicating an exceedance of the
maximum tolerated dose (Bermudez et al., 2012; Williams et al.,
2000). Conversely, there was a decrease in relative testis weight
in a 2-wk study by Dong-mei et al. (2009). However, the weight
difference was not seen in a companion 4-wk experiment and
the magnitude of the change in the 2-wk experiment was the same
at all doses of MTBE making the ﬁnding suspect. As noted in the
discussion of the estrogen agonist hypothesis, testis histopathology
differences were only noted in one rat study (Li et al., 2008), how-
ever, there were no details in the report concerning severity and
incidence of the ﬁnding. No difference from control in epididymi-
des weight or histopathology was observed in any study (Table 3).
No change in prostate and seminal vesicle weight was already
noted in the rank 1 endpoint evaluation of a Hershberger-like
study (de Peyster et al., 2003). In rank 2, additional studies that
measured the weights of these two organs in intact rodents were
added to the table (Table 3). The only change in weight was a slight
but statistical decrease at the highest dose (1600 mg/kg BW/d) in
one 4-wk experiment in one study assessing prostate weight
(Dong-mei et al., 2009). This was not observed at an earlier time
point in a companion experiment, and neither experiment resulted
in a clear dose response so the decrease in weight could have been
an incidental ﬁnding.
In the rank 2 endpoints in the ﬁsh study, no differences com-
pared to controls in concentrations of VTG were observed in female
fathead minnow and zebraﬁsh. There were no gonadal histopathol-
ogical ﬁndings of note with fathead minnows, however, there was
an increase in oocyte atresia in the zebraﬁsh study (Mihaich et al.,
in preparation). As previously noted, changes in gonadal histopa-
thology that are in relative isolation to related corroborative
responses can be the result of other toxic stressors apart from pri-
mary perturbation of endocrine relevant pathways and some
oocyte atresia is relatively common even in control ﬁsh
(McCormick et al., 1989; Hunter and Macewicz, 1985;
Henderson, 1963). In rank 3 endpoints, fecundity was decreased
in zebraﬁsh but not fathead minnow, while there were no effects
in either species with regard to fertilization success, GSI, and
behavior (Table 3).
The in vitro AR binding was considered a rank 2 endpoint for
androgen agonists in the Borgert et al. (2014) paper even though
the assay does not indicate what kind of activity might result from
binding to the receptor. The caveat was that if binding occurred,
the collective WoE would be necessary to identify the potential
MoA for the compound. In the current assessment, AR binding is
considered a rank 3 endpoint to be consistent with the placement
of the ER binding study. MTBE was a non-binder with the androgen
receptor (de Peyster et al., 2014) (Table 3). Two guideline in vitro
screens, considered rank 3 endpoints, were performed to identify
impacts on the steroidogenic pathway. One is the steroidogenesis
screen that detects both inducers and inhibitors of enzymes
responsible for the production of male and female steroid sex hor-
mones (US EPA, 2009f). The endpoints in this cell-based screen are
testosterone and estradiol concentrations (Table 3). MTBE does not
interfere with steroidogenesis as measured by steroid hormone
concentrations in H295R cells (de Peyster et al., 2014). Aromatase
is an enzyme complex responsible for estrogen biosynthesis, con-
verting androgens to estrogens in the steroidogenic pathway. The
screen detects chemicals that inhibit aromatase activity. MTBE
did not inhibit aromatase activity (de Peyster et al., 2014) (Table 3).
There are many endpoints that are listed as rank 3 for the
androgen agonist hypothesis. Given that the ranks 1 and 2 end-
points are predominately negative, suggesting that MTBE does
not have the potential to act as an androgen agonist, a few of the
rank 3 endpoints will be discussed to add additional support tothe higher ranked results. Although androgen agonists can
decrease testosterone concentrations (O’Connor et al., 2000), hor-
monal measures are a rank 3 endpoint because there are a number
of confounding factors that can impact circulating concentrations
including overt toxicity, food intake, and metabolic enzyme induc-
tion (Marty, 2013; Laws et al., 2007). Testosterone concentrations
were measured in a number of studies with both rats and mice
(Table 3). There were statistically signiﬁcant reductions in circulat-
ing concentrations reported in a few experiments at the highest
dose levels although there was not a consistent response even
within other experiments reported by the same authors (Li et al.,
2008; de Peyster et al., 2003; Williams et al., 2000). MTBE exposure
in vivo increased activity of testosterone biotransformation
enzymes in rat liver microsomes (Williams and Borghoff, 2000),
the implication being that catabolism and elimination could be fas-
ter after exposure to MTBE so circulating concentrations would be
reduced. However, comparing studies where there were reported
differences from controls in testosterone concentrations with rank
2 responses in testes and epididymides weights and histopathol-
ogy, prostate weight, and seminal vesicle weight highlights the
lack of concordance in hormonal and organ responses.
The androgen agonist, testosterone, has been shown to increase
uterine weight and uterine stromal cell proliferation, increase
serum testosterone and prolactin, and decrease serum FSH and
LH in the pubertal female study (O’Connor et al., 2000). However,
in a similar study by Kim et al. (2002), exposure to testosterone
at 0.05, 0.2, and 1.0 mg/kg/day by subcutaneous injection resulted
in a decrease in uterine (top two doses) and ovarian (all three
doses) weights albeit at lower doses than employed in the
O’Connor et al. (2000) study. Divergent responses in similar studies
reduces the weight that can be attributed to the endpoint for the
hypothesis which is a reason that hormone concentrations have
been considered a rank 3 endpoint. In studies with MTBE, uterine
weight was either not changed or decreased compared to controls
(Table 3).
No effect in the rank 1 endpoints from the Hershberger-like
assay and the FSTRA, no binding in the rank 2 AR binding assay
and inconsistent responses in other in vivo rank 2 endpoints such
as testis weight and histopathology and rank 3 endpoints (e.g.
uterus and ovary weight, histopathology, testosterone concentra-
tions) are not supportive of MTBE having the potential to act as
an androgen agonist.
4.4. Androgen antagonist hypothesis
Ranks 1 and 2 endpoints for the mammalian studies in the
androgen antagonist hypothesis are the same as for the androgen
agonist hypothesis (Table 4). In the study performed in a similar
manner to a Hershberger method (de Peyster et al., 2003), andro-
gen-dependent organs weighed from rats treated with MTBE and
testosterone propionate were not different from those receiving
testosterone propionate only. The two studies showing an increase
in relative (but not absolute) testis weight (Bermudez et al., 2012;
Williams et al., 2000), one reporting a decrease (Dong-mei et al.,
2009) in relative testis weight (absolute weight not provided for
comparison), and one reporting unusual testis appearance at the
microscopic level (Li et al., 2008) but without sufﬁcient detail,
make these ﬁndings equivocal, as discussed in the previous section.
No differences from control in epididymides weight and histopa-
thology, and seminal vesicle weight, were observed in any study.
Prostate weight, a rank 2 endpoint, was decreased in one rat study
(Dong-mei et al., 2009) although using a very high dose of MTBE
(1600 mg/kg BW/day), while many others reported no change
(Table 4). Other than the few inconsistent changes, rank 1 and 2
mammalian endpoints are not affected by MTBE exposure in a
way that suggests androgen antagonism.
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the agonist hypothesis. There are no endpoints considered appro-
priately sensitive and speciﬁc to be rank 1 in the FSTRA. Rank 2
endpoints are an increase in female VTG, a decrease in male sec-
ondary sex characteristics, and changes in gonad histopathology
indicative of an androgen antagonist. No changes in female VTG
or male secondary sex characteristics were observed in the FSTRA
studies with fathead minnow and zebraﬁsh (Mihaich et al., in
preparation). Reduced oocyte maturation is a hallmark of antian-
drogen exposure in ﬁsh (Martinovic´ et al., 2008; US EPA, 2007).
In the zebraﬁsh study, the increase in oocyte atresia along with a
statistically signiﬁcant increase in the accumulation of oocyte deb-
ris in the oviduct could indicate exposure to an androgen antago-
nist. Given the previous discussion of oocyte atresia being a
common occurrence in ﬁsh and often related to general toxicity
or stress unrelated to a sex hormone pathway and the lack of
any other androgen sensitive response in the ﬁsh studies, it is unli-
kely that MTBE is exhibiting a potential to act as an androgen
antagonist. Rank 3 endpoints were discussed with respect to the
androgen agonist hypothesis and a similar discussion could be
made here. However, no rank 1 endpoint was impacted by expo-
sure to MTBE and the lack of consistent androgen antagonist
effects in the rank 2 rodent and ﬁsh endpoints suggest that MTBE
is not acting like an antiandrogen.
4.5. Thyroid agonist hypothesis
Borgert et al. (2014) list asynchronous development and thyroid
histopathology in Xenopus tadpoles from the amphibian metamor-
phosis assay (AMA) (US EPA, 2009g) as rank 1 endpoints for the
thyroid agonist hypothesis. No relevant amphibian studies with
rank 1 endpoints exist for MTBE.
Rank 2 endpoints include thyroid weight and blood hormone
concentrations in both female and male rodents (Table 5). No dif-
ferences compared to controls were identiﬁed with respect to thy-
roid weight in either female rats or mice. Of the six MTBE studies
that reported thyroid weight in males, three reported no effect
(Dodd et al., 2013; Chun and Kintigh, 1993; Bermudez et al.,
2012 (13-wk study)). One detected an increase in relative thy-
roid:body weight and thyroid:brain weight ratios, although there
was also a signiﬁcant reduction in body weight at the same dose
(800 mg/kg by gavage) which could contribute to the greater
organ:body weight ratio. Another study detected a decrease in
absolute weights of thyroid/parathyroid in males but weight was
not signiﬁcantly different from controls when normalized to body
weight (Bermudez et al., 2012 (1 year study)). The thyroid hor-
mones T3, T4 and TSH were measured in one study with mice
(Chun and Kintigh, 1993) and two studies in rats (Dodd et al.,
2010; Williams et al., 2000 (males only)). No differences compared
to controls were identiﬁed in females with respect to T3, T4, and
TSH measurements. In males, thyroid hormone measurements
were primarily unchanged although there were some increases
and/or decreases in a few studies. The effects of thyroid hormone
are complex making it difﬁcult to ﬁrmly establish an expected pat-
tern of response. However, of the studies that reported changes
compared to controls in T4, T3 or TSH concentrations, T4 and
TSH increased while T3 was not impacted in one study and only
in males (Chun and Kintigh, 1993), the decrease in T4 in
Bermudez et al. (2012) was only observed in the high dose on
day 28 of a 13-week study, and T3 was decreased in only one
experiment of a multiple experiment study (Williams et al.,
2000) with no supporting changes in T4 and TSH and no measure-
ment of thyroid weight or histopathology. In other words, any thy-
roid hormone or weight changes reported were neither consistent
nor accompanied by supporting evidence of thyroid histopathol-
ogy. Tentative conclusions from rank 2 endpoints are suggestivethat MTBE is not exhibiting a potential to act as a thyroid agonist,
however, consulting rank 3 endpoints will help to add conﬁdence
in the assessment.
Pituitary weight is a rank 3 endpoint. Like thyroid weight, pitu-
itary weight was primarily unchanged, although there are two
studies with conﬂicting results. Williams et al. (2000) reported
an increase in pituitary weight after doses of 1500 mg/kg BW/day
MTBE for 2 weeks. This increase was seen in only one of six studies
with male rats that reported weights of pituitary, including two
companion experiments, one 15-day and one 28-day, conducted
by the same investigators where no weight change was seen. A
decrease was seen in the other study, this one using female mice
(Moser et al., 1998). Thyroid histopathology was considered a rank
3 endpoint, primarily because not enough information has been
documented yet about expected patterns of response to distin-
guish agonists from antagonists. However, given there are no
observed effects on thyroid histopathology in conjunction with
no consistent effects in the rank 2 thyroid weight and hormone
measurements, there is good support for MTBE not interacting
with the thyroid pathway in rodents.
In a one-dose study at 100 mg/L, weights of tadpoles and frogs
were increased and time to metamorphosis was reduced by 2 days
compared to controls after exposure to MTBE (Paulov, 1987). The
lack of coincident information on thyroid histopathology and spe-
ciﬁc measurements on other growth parameters make these apical
endpoints difﬁcult to put into context in the WoE and can only be
viewed as corroborative in the entire WoE analysis.
In summary, the consistent rank 2 endpoints along with little or
no change in pituitary weights and no impacts on pituitary and
thyroid histopathology are suggestive that MTBE is not exhibiting
a potential to act as a thyroid agonist.
4.6. Thyroid antagonist hypothesis
Metamorphosis and thyroid histopathology in amphibians and
thyroid weight and histopathology in rodents are rank 1 endpoints
for the thyroid antagonist hypothesis. As was stated for the thyroid
agonist hypothesis, no relevant amphibian studies are available. No
differences from controls for the female rodent endpoints of thy-
roid weight and histopathology were noted in studies with either
rats or mice. In male rodent studies, no histopathology differences
between control and MTBE treated rats and mice were observed.
Thyroid weight was primarily unchanged although there are two
studies with conﬂicting results (e.g., an increase in thyroid weight
in one and a decrease in the other).
Similar conﬂicting results were seen in rank 2 endpoints where
thyroid hormone measurements were primarily unchanged as
noted in the previous discussion under the thyroid agonist hypoth-
esis. In females, there was no change in ovary weights in a number
of studies in rats but there was a decrease in ovary weight in two
studies with mice (Moser et al., 1996, 1998) which would be
expected with a thyroid antagonist (Marty et al., 1999). In males,
thyroid hormone measurements were primarily unchanged
although there were some increases and/or decreases in a few
studies that did not ﬁt a consistent pattern (Table 6).
No consistent patterns were evident when considering the
rodent experiments that measured ranked thyroid endpoints and
reported any statistically signiﬁcant ﬁndings, all at very high doses
(Table 6). The inconsistencies could simply be indicative of inci-
dental ﬁndings; limitations of single-time point thyroid hormone
measurements; different levels of stress; weight gain suppression
in the test animals; and/or other systemic toxicities co-occurring
in animals in different experiments. Closer scrutiny was warranted
to avoid overlooking any more subtle signs of known modes of
action involving the thyroid; for example, liver enzyme induction
with secondary effects on thyroid (Marty, 2013). If this were the
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trilobular hepatic hypertrophy, indicating increased liver P450 and
suggesting faster catabolism of T4/T3, increased TSH as a conse-
quence of that, and, if that occurs, an expectation of some sign of
effect in the thyroid itself like increased weight or hyperplasia of
follicular cells. Both liver and thyroid endpoints had to be mea-
sured in the same test animals for this comparison to be meaning-
ful. After reviewing the studies that reported on one or more key
endpoints for both thyroid and liver that are necessary to demon-
strate applicability of that MoA, this thyroid–liver connection that
has been identiﬁed as relevant to some potent P450 inducers
apparently does not apply to MTBE. This is perhaps not too surpris-
ing insofar as MTBE is recognized as only a weak liver enzyme
inducer.
Similar to the thyroid agonist hypothesis, the lack of any consis-
tent change in the rank 1 thyroid weight and histopathology
results, no difference in the rank 2 female thyroid hormone mea-
surements in both rats andmice and the conﬂicting changes in thy-
roid hormones in the male studies suggest that MTBE does not
have thyroid antagonist properties.
4.7. Steroidogenesis induction hypothesis
This hypothesis refers speciﬁcally to the synthesis of steroids
in the estrogen and androgen pathways by steroid-producing
endocrine organs. Although corticosterone is a steroid produced
by adrenal glands, blood concentrations of corticosterone, adrenal
weights and histopathology are not currently considered diagnos-
tic of endocrine modes of action (OECD, 2012) Steroidogenesis
also does not include how steroids are handled by the body after
they are produced (e.g., concentrations and binding to sex hor-
mone binding globulin produced primarily in liver, or catabolism
and excretion of steroids, all of which are largely dependent on
non-endocrine organs). Information on expected responses to a
chemical that induces steroidogenesis is lacking, thus no rank 1
endpoints were identiﬁed (Table 7). To address the possibility
that MTBE would interact with the steroidogenic pathway, estra-
diol and testosterone concentrations from the guideline in vitro
steroidogenesis study were identiﬁed as rank 2 endpoints. MTBE
was classiﬁed negative for effects on testosterone and estradiol
in the steroidogenesis assay. In the Borgert et al. (2014) relevance
rankings, testosterone concentrations in the male pubertal assay
are considered a rank 3 endpoint as it could be assumed that ste-
roid hormone concentrations would increase with inducers of ste-
roidogenesis. Only testosterone and thyroid hormones are
evaluated in the in vivo EDSP assays, otherwise estradiol would
also be relevant as a rank 3 corroborative endpoint so we
included it as additional evidence. Plasma testosterone and estra-
diol concentrations from male and female rodent studies with
MTBE could thus, potentially be supportive of the in vitro
responses. Only one experiment of two reported in the same
study has reported an increase in testosterone concentration (Li
et al., 2008). The rest of the supporting studies either reported
no changes or a decrease in testosterone concentrations com-
pared to controls. No change has been seen in estradiol concen-
trations when measured in female mice. A signiﬁcant increase
in circulating estradiol was seen in only one of three male rodent
experiments in which this has been measured. Ongoing adjust-
ments occurring at the level of the hypothalamus and pituitary
to maintain normal circulating concentrations make it especially
important to see consistency in blood hormone results in multiple
studies. The activity and mRNA of aromatase, a steroidogenic
enzyme, have been measured in tissues from male rats treated
with high doses of MTBE. Results have been mixed, with activity
decreased in a study with only one high (1200 mg/kg) MTBE dose
group (de Peyster et al., 2003) but not statistically different in amore extensive follow up experiment (de Peyster et al., 2014),
and mRNA showing an increasing tendency in testis related to
dose that was statistically signiﬁcant but with a weak correlation,
and no effect in liver – none of which consistently supports sig-
niﬁcant aromatase induction. The lack of effect in the in vitro ste-
roidogenesis assay along with the lack of consistent hormonal
response in the in vivo rodent studies suggests that MTBE is not
inducing steroidogenesis.4.8. Steroidogenesis inhibition hypothesis
Similar to the steroidogenesis induction hypothesis, no rank 1
endpoints were identiﬁed for the steroidogenesis inhibition
hypothesis (Table 8). Hormone concentrations in the in vitro steroi-
dogenesis assay as well as female VTG and male gonad histopa-
thology in the FSTRA are considered sensitive and speciﬁc
enough endpoints to be rank 2. There were no differences from
controls in estradiol or testosterone concentrations in the steroido-
genesis study. Similarly, in the ﬁsh study there were no effects on
female VTG or male gonadal histopathology.
There are many rank 3 endpoints for the steroidogenesis inhibi-
tion hypothesis. Aromatase inhibition in the aromatase in vitro
assay is a strong corroborative endpoint in the hypothesis as it
directly relates to the conversion of testosterone to estradiol, how-
ever it is only one speciﬁc step in the pathway thus was considered
a rank 3 endpoint. While Borgert et al. (2014) did not include male
androgen-dependent weights, Stoker and Zorrilla (2010) and
O’Connor et al. (2002b) both noted that the steroidogenesis inhib-
itor ketoconazole reduced the weight of androgen-dependent tis-
sues in both the pubertal male study and the 15-day intact adult
male study. For completeness, testis, prostate, and seminal vesicle
weights, as well as hormone concentrations, aromatase activity
and mRNA from in vivo rodent studies have been listed as rank 3
endpoints from the MTBE studies. Using the Borgert et al. (2014)
approach we would not need to consider their response because
they are much less sensitive and speciﬁc for the hypothesis. In
summary, the lack of consistent supporting statistically signiﬁcant
ﬁndings in steroid hormone measurements from rank 3 studies,
the preponderance of no effects reported in steroid hormone-
dependent organ weights or histology, as well as the absence of
impacts on aromatase and steroidogenesis enzyme activity
in vitro and the ﬁsh study in vivo, suggest that it is unlikely that
MTBE is inhibiting steroidogenesis.5. Discussion
The deﬁnition of an endocrine disruptor is a substance that alters
endocrine system function and consequently causes adverse health
effects in an intact organism, or its progeny or in (sub) populations
(WHO, 2002). We are now in a position to characterize the many
responsesseenasaconsequenceofexposuretoMTBEinexperiments
using rodent and ﬁsh models. Using a transparent and systematic
WoE approach, the eight endocrine pathway hypotheses have been
tested with the large database available for MTBE. Of the rank 1 and
2 endpoints for the eight hypotheses, no consistent pattern emerged
that supported agonistic or antagonistic effects ofMTBEonestrogen,
androgen, thyroid or steroidogenesis pathways. The majority of the
endpoints were not different in MTBE-treated animals relative to
the controls in the clear majority of the studies. Many of the studies
are long-term – 13-weeks to 1–2 years. Most tests used adults but
some testing used young animals, providing an opportunity to
observe differences if they were occurring. In addition, in a series of
studies comparing sensitivity of adults to pubertal animals,
O’Connor et al. (2002a,b, 2000) used positive control compounds in
a 15-day intact male assay to compare to the response of the male
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endocrineactivechemicals.Aprimaryendpoint inthepubertal study
not assessed in the adult study is onset of puberty. Using patterns of
hormonal response and histopathology, the authors of that
comparison study concluded that the ability of the intact adultmale
study to identify a potential MoA was comparable to that of the
pubertal studies for the positive control compounds used. So, while
puberty onsetmeasurements are not available forMTBE, thewealth
of existing hormonal and histopathological data provides sufﬁcient
information to assess potentialMoA.
A few of the MTBE reproductive and pre-/post-natal develop-
mental effects studies (Bevan et al., 1997a; Biles et al., 1987),
and also a more recent publication describing a 2-year carcinoge-
nicity bioassay of MTBE (Dodd et al., 2013) provided some addi-
tional endocrine organ-speciﬁc weight and histopathology
information that could be ranked. As was noted earlier, these
types of studies, and also a comprehensive neurotoxicological
guideline GLP evaluation of MTBE (Daughtrey et al., 1997),
provide many other apical effects endpoints, such as fertility
and reproductive indices, fetal examination results, neuropathol-
ogy evaluation with behavioral correlates, and tumor incidences
that were not ranked. Despite not being ranked, they contribute
substantially to a more general assessment of a chemical’s ability
to cause an adverse effect possibly by some endocrine system
perturbation even if they do not identify an MoA or distinguish
between endocrine agonistic and antagonistic properties. The
absence of any signiﬁcant adverse ﬁndings in these types of
studies, especially if consistent across studies as is the case with
MTBE, lends support for the position that this chemical has nei-
ther agonist nor antagonistic interactions with the hormonal
pathways examined in detail in this analysis. In addition, no
endocrine organ has been unequivocally recognized as a target
of MTBE in carcinogenicity bioassays.
Because MTBE appears to have had some sporadic effects on
endocrine endpoints in some of the studies we reviewed, the ques-
tion of what could cause this other than a direct effect on the endo-
crine system should be addressed. Several MTBE study endpoints
do not appear in the hypothesis ranking tables because they were
not considered sufﬁciently related to endocrine activity or, even if
related, could not help to distinguish between agonist and antago-
nist behavior. However, they are worth mentioning because these
additional responses seen concurrently with more speciﬁcally
endocrine organ-related effects are consistent with the idea that
at least the high dose MTBE-treated animals experience
signiﬁcantly more stress than vehicle-treated controls. Most of
the studies reviewed report one or more effects associated with
non-endocrine organ toxicities. Those that could impact the
endocrine system as well include central nervous system distur-
bances (manifested as transient lethargy, hypoactivity, ataxia,
and lack of startle response), signiﬁcant reductions in body weight
gain, dehydration, increased adrenal gland weights, elevated
serum corticosterone, and microscopic changes in adrenal glands
(speciﬁcally loss of zona reticularis) (Dodd and Kintigh, 1989;
Robinson et al., 1990; IIT Research Institute, 1992; Chun and
Kintigh, 1993; Daughtrey et al., 1997; Lington et al., 1997; Bird
et al., 1997; Bevan et al., 1997a,b; Moser et al., 1998; Zhou and
Ye, 1999; Williams and Borghoff, 2000; Williams et al., 2000; de
Peyster et al., 2003, 2008, 2014; Dong-mei et al., 2009). Exposures
at which one or more of these occur are in the range of
3000–8000 ppm by inhalation, and 800–1600 mg/kg BW/day
when MTBE is given by gavage. It should probably be clariﬁed here
that changes in corticosterone are not considered to be evidence of
endocrine modulation by the tested substance when general stress
is known or suspected as the likely underlying cause.
Stress responses in both female and male rodents include
decreased concentrations of gonadotropin-releasing hormone(GnRH), gonadotropin hormones (FSH and LH), gonadal sex ste-
roids (testosterone, progesterone, and estradiol) (Everds et al.,
2013). Using immobilization of male rats to create repeated stress,
although of temporary duration, researchers have found higher
plasma concentrations of corticosterone and progesterone,
reduced body weight gain, lipid depletion of the zona fascicularis
of the adrenal glands, and lower plasma concentrations of the
androgens testosterone and androstenedione (Pellegrini et al.,
1998). Microscopic examination of the testes of those stressed ani-
mals revealed disorganized seminiferous tubular epithelium and
enlargement of the interstitial spaces with considerable individual
variability in extent and severity of the damage. ‘‘Disordered
arrangement of seminiferous epithelium’’ is also how the investi-
gators described their ﬁndings in the only MTBE study that
reported abnormal testis in male rats, in that case after daily
gavage with 800 or 1600 mg/kg BW/d MTBE for 28-days (Dong-
mei et al., 2009). In reviewing that study, we also noted a surpris-
ing number of mortalities (3 of 10) in the lowest 400 mg/kg/day
MTBE dose group and even one vehicle control animal, suggesting
the possibility of improper or inconsistent gavaging. Caution is
advised when interpreting effects that could be related to a general
stress response (Everds et al., 2013), and this study is but one
example of an MTBE study where stress may be the underlying
cause.
Daily gavaging of animals is a common and accepted method in
toxicology studies, but it still causes stress even if done properly
(Brown et al., 2000). Unexpected test animal mortality is not
uncommon especially in studies of MTBE administered by gavage,
and gavage errors are not always distinguished from chemically-
caused deaths in all study reports. Vehicle-treated animals are also
gavaged to control for stress, but MTBE has a very pungent taste
and odor and a low taste and odor threshold. Therefore, one can
imagine an experimental animal gavaged with MTBE, regardless
of the dose, might ﬁnd that experience more stressful than being
gavaged only with vehicles used in the MTBE studies.
Decrements in body weight can also confound interpretation of
potential compound-related effects on the endocrine system (de
Peyster et al., 2014; O’Connor et al., 2000). Signiﬁcantly reduced
ﬁnal body weights relative to controls are often reported along
with endocrine endpoints in MTBE experiments using rodents.
Reduced concentrations of testosterone can be a function of sup-
pressed body weight gain (Bergendahl et al., 1989; Chen et al.,
2005). Decreased production of LH, FSH, estrogen and thyroid hor-
mones has also been shown in studies on food restriction in
rodents (Ahmed et al., 2012; Boelen et al., 2008). Even when a
study does not report a statistically signiﬁcant difference between
control and treated animal body weights, further comparison of
mean body weight gains across the test groups – which not all
studies report but can often be ascertained from data provided –
sometimes reveals markedly reduced weight gain in MTBE groups
relative to controls.
In an attempt to fully understand underlying causes of the rel-
atively few effects seen in endocrine organs after exposure to high
doses of MTBE, an additional alternative explanation proposed
involves the liver as a primary target with secondary effects on
the endocrine system. This idea has been introduced in several
WoE hypothesis discussions. Reduced concentrations of hormones,
including estrogens, androgens, and TSH in serum, can occur when
the enzymes involved in their catabolism are induced. Experiments
focusing on steroid metabolic enzymes have demonstrated an abil-
ity of MTBE to increase total P450 and more speciﬁcally activity of
enzymes involved in estradiol and testosterone metabolism (Moser
et al., 1996; Williams and Borghoff, 2000). MTBE is not considered
a strong inducer. Furthermore because it appears to accelerate its
own metabolism (Williams and Borghoff, 2000), over time the
degree of induction and its consequences would diminish. Varying
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could explain dissimilar effects on endocrine endpoints along with
other plausible explanations like differences in reduction of body
weight gain and different degrees of stress experienced by the test
animals.
In summary, this analysis represents an attempt to systemati-
cally gather, analyze and weigh all evidence currently available
related to potential endocrine activity of MTBE. Several investiga-
tors (including one of the authors) have conducted experiments
in rodent and ﬁsh models and found some hormone concentrations
and other endocrine-related endpoints changed with high doses of
MTBE; however, one must remember that hormone concentrations
alone, or isolated reports of other changes that do not show dose
response or are not conﬁrmed by multiple other studies, should
never be assumed to demonstrate an endocrine system effect. To
reach scientiﬁcally justiﬁed conclusions based on the totality of
in vitro and in vivo evidence, this WoE procedure involved a
semi-quantitative relevance weighting of each endpoint for each
hypothesis and a systematic consideration of each endpoint in a
variety of different study designs. The totality of the evidence thus
far does not support a direct effect on the endocrine system in
terms of the hypotheses tested. A weight of evidence approach is
therefore essential for revealing potential endocrine effects of
MTBE.
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